Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.

Conference Call & Webcast Detail:

Date: Thursday, May 14, 2026
Time: 8:30 a.m. Eastern Time
Webcast Link:https://edge.media-server.com/mmc/p/2iptdco4
Participant Link: https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3

To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.

PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.

For more information, please visit www.fennecpharma.com and follow on LinkedIn.

For further information, please contact:

Investors:

Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate and Media:

Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
[email protected]



Playtika Holding Corp. Reports Q1 2026 Financial Results


Revenue of $744.7 million and Direct-to-Consumer (“DTC”) Revenue of $291.8 million



Revenue Increased 9.7% Sequentially and 5.5% Year Over Year



DTC Platforms Revenue Increased 16.7% Sequentially and 62.8% Year Over Year

HERZLIYA, Israel, May 07, 2026 (GLOBE NEWSWIRE) — Playtika Holding Corp. (NASDAQ: PLTK) today released financial results for its first quarter for the period ending March 31, 2026.


Financial Highlights

  • Revenue of $744.7 million increased 9.7% sequentially and 5.5% year over year.
  • Record DTC platforms revenue of $291.8 million increased 16.7% sequentially and 62.8% year over year.
  • Net Loss of $(57.5) million and Adjusted Net Income of $13.6 million.
  • Net Loss reflects a non-cash impact from contingent consideration remeasurement related to the earnout payment tied to the SuperPlay acquisition.
  • Adjusted EBITDA of $125.2 million decreased (37.8)% sequentially and (25.2)% year over year.
  • Cash, cash equivalents, and short-term investments totaled $779.2 million as of March 31, 2026.

“We delivered a strong start to 2026, led by continued momentum in Disney Solitaire and another quarter of record breaking performance in Direct-to-Consumer,” said Robert Antokol, Chief Executive Officer. “Just as importantly, we are seeing signs of improved stability across our organic portfolio quarter over quarter. We remain focused on disciplined execution, investing behind the opportunities we believe can drive sustained engagement and long-term value creation.”

“Q1 performance is ahead of our prior expectations, with SuperPlay tracking ahead of plan and the core portfolio showing strength,” said Tae Lee, Chief Financial Officer. “Our Adjusted EBITDA for the quarter reflects a planned, front-loaded investment cadence as SuperPlay scales, which we expect to normalize over the year.”


Board Appoints Tae Lee as Chief Financial Officer

The Board of Directors has appointed Tae Lee as Chief Financial Officer, effective May 5th, following his service as Acting Chief Financial Officer since April 2026.


Selected Operational Metrics and Business Highlights

  • Average Daily Paying Users of 387K increased 8.4% sequentially and decreased (0.8)% year over year.
  • Average Payer Conversion of 4.5%, consistent with Q4 2025 conversion and up from 4.3% in Q1 2025.
  • Bingo Blitz revenue of $153.7 million decreased (3.0)% sequentially and (5.4)% year over year.
  • Disney Solitaire revenue of $123.3 million increased 72.1% sequentially.
  • June’s Journey revenue of $76.0 million increased 8.7% sequentially and 10.4% year over year.
  • All-time high in revenue and DTC platforms revenue.


Financial Outlook

We are raising our full-year 2026 guidance to $2.75 – $2.85 billion (from $2.70 – $2.80 billion) and increasing our Adjusted EBITDA range to $750 – $790 million (from $730 – $770 million).


Conference Call

Playtika management will host a conference call at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) today to discuss the company’s results. The conference call can be accessed via a webcast accessible at investors.playtika.com. A replay of the call will be available through the website one hour following the call and will be archived for one year.

Summary Operating Results of Playtika Holding Corp.

  Three months ended March 31,

(in millions, except percentages, Average DPUs, and ARPDAU)
  2026       2025  
Revenues $ 744.7     $ 706.0  
Total costs and expenses $ 794.3     $ 638.2  
Operating income (loss) $ (49.6 )   $ 67.8  
Net income (loss) $ (57.5 )   $ 30.6  
Adjusted EBITDA $ 125.2     $ 167.3  
Net income margin (7.7)%     4.3 %
Adjusted EBITDA margin   16.8 %     23.7 %
       
Non-financial performance metrics      
Average DAUs   8.6       9.0  
Average DPUs (in thousands)   387       390  
Average Daily Payer Conversion   4.5 %     4.3 %
ARPDAU $ 0.94     $ 0.87  
Average MAUs   30.1       31.8  

  

About Playtika Holding Corp.

Playtika (NASDAQ: PLTK) is a mobile gaming entertainment and technology market leader with a portfolio of multiple game titles. Founded in 2010, Playtika was among the first to offer free-to-play social games on social networks and, shortly after, on mobile platforms. Headquartered in Herzliya, Israel, and guided by a mission to entertain the world through infinite ways to play, Playtika has employees across offices worldwide.

Forward Looking Information

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this press release, including statements regarding our business strategy, plans and our objectives for future operations, are forward-looking statements. Further, statements that include words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “intend,” “intent,” “may,” “might,” “potential,” “present,” “preserve,” “project,” “pursue,” “should,” “will,” or “would,” or the negative of these words or other words or expressions of similar meaning may identify forward-looking statements.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties and assumptions, including, but not limited to, the risks and uncertainties discussed in our filings with the Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment and industry. As a result, it is not possible for our management to assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking statements discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated, predicted or implied in the forward-looking statements.

Important factors that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include without limitation:

  • actions of our majority shareholder or other third parties that influence us;
  • our reliance on third-party platforms, such as the iOS App Store and Google Play Store, to distribute our games and collect revenues, and the risk that such platforms may adversely change their policies;
  • our reliance on a limited number of games to generate the majority of our revenue;
  • our reliance on a small percentage of total users to generate a majority of our revenue;
  • our free-to-play business model, and the value of virtual items sold in our games, is highly dependent on how we manage the game revenues and pricing models;
  • our inability to refinance our indebtedness, including, without limitation, our $550 million revolving credit facility which is set to expire in March 2027, or to obtain additional financing on favorable terms or at all;
  • our inability to identify acquisition targets that fit our strategy or complete acquisitions and integrate any acquired businesses successfully or realize the anticipated benefits of such acquisitions could limit our growth, disrupt our plans and operations or impact the amount of capital allocated to mergers and acquisitions;
  • our ability to compete in a highly competitive industry with low barriers to entry;
  • our ability to retain existing players, attract new players and increase the monetization of our player base;
  • our ability to develop and/or launch new products and content or otherwise execute against our product roadmap strategy;
  • we have significant indebtedness and are subject to the obligations and restrictive covenants under our debt instruments;
  • the impact of an economic recession or periods of increased inflation, and any reductions to household spending on the types of discretionary entertainment we offer;
  • our controlled company status;
  • legal or regulatory restrictions or proceedings could adversely impact our business and limit the growth of our operations;
  • risks related to our international operations and ownership, including our significant operations in Israel and Ukraine and the fact that our controlling stockholder is a Chinese-owned company;
  • geopolitical events such as the Wars in Israel and Ukraine;
  • our reliance on key personnel;
  • market conditions or other factors affecting the payment of dividends, including the decision whether or not to pay a dividend;
  • uncertainties regarding the amount and timing of repurchases under our stock repurchase program;
  • security breaches or other disruptions could compromise our information or our players’ information and expose us to liability; and
  • our inability to protect our intellectual property and proprietary information could adversely impact our business.
       
PLAYTIKA HOLDING CORP.

CONSOLIDATED BALANCE SHEETS

(In millions, except par value)
       
  March 31,   December 31,
    2026       2025  
  (Unaudited)    
ASSETS      
Current assets      
Cash and cash equivalents $ 779.2     $ 684.2  
Short-term investments         136.0  
Restricted cash   1.5       1.5  
Accounts receivable   180.0       161.8  
Prepaid expenses and other current assets   108.2       80.4  
Total current assets   1,068.9       1,063.9  
Property and equipment, net   96.4       102.9  
Operating lease right-of-use assets   118.6       124.2  
Intangible assets other than goodwill, net   401.0       425.7  
Goodwill   1,695.7       1,695.7  
Deferred tax assets, net   173.7       173.2  
Investments in unconsolidated entities   17.3       17.5  
Other non-current assets   115.3       115.8  
Total assets $ 3,686.9     $ 3,718.9  
       
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)      
Current liabilities      
Current maturities of long-term debt $ 11.1     $ 11.1  
Accounts payable   87.3       80.3  
Contingent consideration   459.0       454.0  
Operating lease liabilities   25.4       27.5  
Accrued expenses and other current liabilities   321.3       395.0  
Total current liabilities   904.1       967.9  
Long-term debt   2,375.4       2,378.0  
Contingent consideration   370.0       280.0  
Operating lease liabilities   108.3       115.4  
Deferred tax liabilities   5.1       8.2  
Other long-term liabilities   387.1       380.8  
Total liabilities   4,150.0       4,130.3  
Commitments and contingencies      
Stockholders’ equity (deficit)      
Common stock of $0.01 par value; 1,600.0 shares authorized; 432.2 and 428.8 shares issued, respectively, and 380.4 and 377.0 shares outstanding, respectively   4.3       4.3  
Treasury stock at cost, 51.8 shares   (603.5 )     (603.5 )
Additional paid-in capital   1,436.2       1,423.1  
Accumulated other comprehensive income   8.6       15.9  
Accumulated deficit   (1,308.7 )     (1,251.2 )
Total stockholders’ deficit   (463.1 )     (411.4 )
Total liabilities and stockholders’ deficit $ 3,686.9     $ 3,718.9  

   
PLAYTIKA HOLDING CORP.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In millions, except for per share data)

(Unaudited)
   
  Three months ended March 31,
    2026       2025  
Revenues $ 744.7     $ 706.0  
Costs and expenses      
Cost of revenue   192.2       197.4  
Research and development   98.0       103.8  
Sales and marketing   360.6       271.8  
General and administrative   143.5       65.2  
Total costs and expenses   794.3       638.2  
Income (loss) from operations   (49.6 )     67.8  
Interest and other, net   24.2       26.7  
Income (loss) before income taxes   (73.8 )     41.1  
Provision for income taxes   (16.3 )     10.5  
Net income (loss)   (57.5 )     30.6  
Other comprehensive income (loss)      
Foreign currency translation         7.2  
Change in fair value of derivatives   (7.3 )     (6.7 )
Total other comprehensive income (loss)   (7.3 )     0.5  
Comprehensive income (loss) $ (64.8 )   $ 31.1  
       
Net income (loss) per share attributable to common stockholders, basic $ (0.15 )   $ 0.08  
Net income (loss) per share attributable to common stockholders, diluted $ (0.15 )   $ 0.08  
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, basic   378.3       375.4  
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders, diluted   378.3       376.0  

   
PLAYTIKA HOLDING CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)

(Unaudited)
   
  Three months ended March 31,
    2026       2025  
Cash flows from operating activities $ 22.8     $ 18.8  
Cash flows from investing activities      
Purchase of property and equipment   (5.7 )     (10.4 )
Capitalization of internal use software costs   (8.9 )     (8.3 )
Purchase of software for internal use   (5.6 )     (6.6 )
Proceeds from short-term investments   135.6        
Purchase of short-term investments         (79.5 )
Other investing activities   0.1       (0.3 )
Net cash provided by (used in) investing activities   115.5       (105.1 )
Cash flows from financing activities      
Dividend paid   (37.7 )     (37.3 )
Repayments on bank borrowings   (4.8 )     (4.8 )
Payment of tax withholdings on stock-based payments   (1.1 )     (0.5 )
Payment for share buyback         (4.8 )
Net cash used in financing activities   (43.6 )     (47.4 )
Effect of exchange rate changes on cash and cash equivalents and
restricted cash
  0.3       2.3  
Net change in cash, cash equivalents and restricted cash   95.0       (131.4 )
Cash, cash equivalents and restricted cash at the beginning of the period   685.7       567.7  
Cash, cash equivalents and restricted cash at the end of the period $ 780.7     $ 436.3  

   
CALCULATION OF FREE CASH FLOW

(In millions)
   
  Three months ended March 31,
    2026       2025  
Cash flows from operating activities $ 22.8     $ 18.8  
Purchase of property and equipment   (5.7 )     (10.4 )
Capitalization of internal use software costs   (8.9 )     (8.3 )
Purchase of software for internal use   (5.6 )     (6.6 )
Free Cash Flow $ 2.6     $ (6.5 )
               

Non-GAAP Financial Measures

Adjusted EBITDA and Adjusted Net Income are non-GAAP financial measures and should not be construed as an alternative to net income as an indicator of operating performance, nor as an alternative to cash flow provided by operating activities as a measure of liquidity, or any other performance measure in each case as determined in accordance with GAAP.

Our Credit Agreement defines Adjusted EBITDA as net income before (i) interest expense, (ii) interest income, (iii) provision for income taxes, (iv) depreciation and amortization expense, (v) impairment charges, (vi) stock-based compensation, (vii) contingent consideration, (viii) acquisition and related expenses, and (ix) certain other items. We calculate Adjusted EBITDA Margin as Adjusted EBITDA divided by revenues.

We define Adjusted Net Income as net income before (i) impairment charges, and (ii) contingent consideration.

Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Net Income as calculated herein may not be comparable to similarly titled measures reported by other companies within the industry and are not determined in accordance with GAAP. Our presentation of Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Net Income should not be construed as an inference that our future results will be unaffected by unusual or unexpected items.



RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA


(In millions)

The following table sets forth a reconciliation of Adjusted EBITDA to net income, the closest GAAP financial measure:

  Three months ended March 31,
    2026       2025  
Net income (loss) $ (57.5 )   $ 30.6  
Provision for income taxes   (16.3 )     10.5  
Interest expense and other, net   24.2       26.7  
Depreciation and amortization   44.9       59.2  
EBITDA   (4.7 )     127.0  
Stock-based compensation(1)   14.1       25.5  
Changes in estimated value of contingent consideration   95.0       6.9  
Acquisition and related expenses(2)   7.2       6.5  
Other items(3)   13.6       1.4  
Adjusted EBITDA $ 125.2     $ 167.3  
Net income margin (7.7)%     4.3 %
Adjusted EBITDA margin   16.8 %     23.7 %

_________
(1) Reflects stock-based compensation expense related to the issuance of equity awards to our employees and Directors.
(2) Includes costs incurred to evaluate and pursue acquisition activities as well as costs incurred by the Company in connection with the evaluation of strategic alternatives.
(3) Amounts for the three months ended March 31, 2026 consists entirely of severance, and the amount for the three months ended March 31, 2025 consists primarily of $0.7 million of severance incurred by the Company.
   

RECONCILIATION OF NET INCOME TO ADJUSTED NET INCOME

(In millions)

The following table sets forth a reconciliation of Adjusted Net Income to net income (loss), the closest GAAP financial measure:

  Three months ended March 31,
    2026       2025  
Net income (loss) $ (57.5 )   $ 30.6  
Changes in estimated value of contingent consideration   95.0       6.9  
Income tax impact of adjustments   (23.9 )     (1.3 )
Adjusted Net Income $ 13.6     $ 36.2  
               

Contacts

Investor Relations    
[email protected]    


Source: Playtika Holding Corp.



Wallbox Obtains Court Approval of its Financial Restructuring Plan

Wallbox Obtains Court Approval of its Financial Restructuring Plan

  • The Commercial Court of Barcelona approves Wallbox’s comprehensive financial restructuring plan

  • The approval represents a key milestone towards the implementation of the Company’s restructuring and execution of its business plan.

BARCELONA, Spain–(BUSINESS WIRE)–
Wallbox N.V. (NYSE: WBX) (“Wallbox” or the “Company”, and together with its consolidated subsidiaries, the “Group”), a global provider of electric vehicle charging and energy management solutions, has obtained court approval from the Commercial Court of Barcelona for its comprehensive financial restructuring plan, which was signed in April 2026.

Following court approval, the restructuring plan is now binding on all affected financial and non-financial creditors of the Group. Upon the completion of certain customary formalities, expected to take place in the coming days, the plan will become fully effective, allowing Wallbox to move forward with implementing its new capital structure and executing its business plan.

The restructuring plan contemplates the refinancing of approximately €169.6 million of the Group’s outstanding financial indebtedness, as well as a capital increase. Overall, this comprehensive refinancing is expected to strengthen Wallbox’s liquidity position and support the continuity of its operations.

Following the completion of the contemplated refinancing, Wallbox will continue to advance its operational improvements and cost initiatives, with a clear focus on advancing towards sustainable profitability.

“We would like to thank our creditors for the trust they have placed in the company throughout this process. With the court approval of the plan and its imminent effectiveness, Wallbox enters a new phase with a clear roadmap, focused on its strategic markets and on executing the necessary measures to move decisively toward profitability,” said Enric Asunción, Co-founder and CEO of Wallbox.

About Wallbox

Wallbox is a global technology company, dedicated to changing the way the world uses energy. Wallbox creates advanced electric vehicle charging and energy management systems that redefine the relationship between users and the network. Wallbox goes beyond charging electric vehicles to give users the power to control their consumption, save money and live more sustainably. Wallbox offers a complete portfolio of charging and energy management solutions for residential, semi-public, and public use in more than 100 countries around the world. Founded in 2015 in Barcelona, where the company’s headquarters are located, Wallbox currently has offices across Europe, Asia, and America. For more information, visit www.wallbox.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the expected timing and completion of Wallbox’s planned restructuring, including the effectiveness of the restructuring plan; the negotiation and execution of definitive agreements contemplated under the restructuring plan on the terms previously described; the expected completion of the capital increase; the anticipated repayment of the bridge loan by set-off against subscription obligations; the Group’s projected cash generation and debt service capacity; and the Group’s ability to implement its business plan following completion of the restructuring.

The words “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “focus,” “forecast,” “intend,” “likely,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the risk that the restructuring plan may not become effective on the anticipated timeline or at all; that the terms of the restructuring may be modified in the course of implementation; as well as Wallbox’s history of operating losses; its ability to obtain adequate capital funding or improve its financial performance, as well as the other important factors discussed under the caption “Risk Factors” in Wallbox’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, as such factors may be updated from time to time in its other filings with the Securities and Exchange Commission (the “SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations section of Wallbox’s website at investors.wallbox.com. Any such forward-looking statements represent management’s estimates as of the date of this press release. Any forward-looking statement that Wallbox makes in this press release speaks only as of the date of such statement. Except as required by law, Wallbox disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Wallbox N.V.

Wallbox Public Relations Contact:

Albert Cabanes

Public Relations

[email protected]


Wallbox Investor Contact:

Michael Wilhelm

Corporate Development & IR

[email protected]

KEYWORDS: Spain Europe

INDUSTRY KEYWORDS: Technology EV/Electric Vehicles Finance Semiconductor Automotive Vehicle Technology Professional Services Alternative Energy Energy

MEDIA:

Logo
Logo

Vontier Announces Agreement to Sell Teletrac Navman

Vontier Announces Agreement to Sell Teletrac Navman

RALEIGH, N.C.–(BUSINESS WIRE)–
Vontier Corporation (NYSE: VNT), a leading global provider of critical technologies and solutions to connect, manage and scale the mobility ecosystem, today announced a definitive agreement to sell a majority of Teletrac Navman, its global telematics and asset management business to private equity firm, Respida Capital, for a purchase price that values the business at $220 million. Vontier will receive $80 million in cash, with the remainder comprised of an interest-bearing seller note and a minority equity stake in the business.

“This transaction reflects our ongoing portfolio simplification efforts and continues Vontier’s transformation into a more focused industrial technology company,” said Mark Morelli, CEO of Vontier. “While this sale marks the end of the business’s journey with Vontier, we are confident Teletrac will continue to thrive within Respida’s portfolio. We are grateful to the team for their dedication to the business, and wish our colleagues continued success under its new leadership.”

“We’re excited to partner with Teletrac and build on its strong momentum,” said James Zubok, Founder and Managing Member of Respida Capital. “Teletrac plays a mission-critical role for fleets and field operations around the world. The company’s broad suite of fleet management solutions, which are built on a modern, AI-enabled platform, help customers make real-time decisions and simplify regulatory complexity. We look forward to leveraging our technology expertise to help Teletrac’s talented team accelerate growth and continue delivering for customers.”

Serving fleet customers across several industries, Teletrac Navman is an end-to-end telematics platform that provides AI-enabled vehicle fleet and asset management solutions – empowering customers to operate their businesses in a safe, sustainable and efficient manner.

Financial results for the business are currently reported within the Mobility Technologies segment of Vontier and will be excluded from continuing operations as of the completion date expected in late Q2.

ABOUT VONTIER

Vontier (NYSE: VNT) is a global industrial technology company uniting productivity, automation and multi-energy technologies to meet the needs of a rapidly evolving, more connected mobility ecosystem. Leveraging leading market positions, decades of domain expertise and unparalleled portfolio breadth, Vontier powers the way the world moves – delivering smart, safe and sustainable solutions to our customers and the planet. Vontier has a culture of continuous improvement and innovation built upon the foundation of the Vontier Business System and embraced by colleagues worldwide. Additional information about Vontier is available on the Company’s website at www.vontier.com.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of the federal securities laws. These statements include, but are not limited to statements regarding Vontier Corporation’s (the “Company’s”) business and acquisition opportunities, anticipated sales growth, anticipated adjusted operating margin expansion, anticipated adjusted net earnings per share, anticipated adjusted cash flow conversion, and anticipated earnings growth, and any other statements identified by their use of words like “anticipate,” “expect,” “believe,” “outlook,” “guidance,” or “will” or other words of similar meaning. There are a number of important risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These risks and uncertainties include, among other things, deterioration of or instability in the economy, the markets we serve, changes in U.S. and international geopolitics, including trade policies, volatility in financial markets, contractions or lower growth rates and cyclicality of markets we serve, competition, changes in industry standards and governmental policies and regulations that may adversely impact demand for our products or our costs, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, impact of divestitures, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with changes in applicable laws and regulations, risks relating to global economic, political, war or hostility, public health, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, security breaches or other disruptions of our information technology systems, adverse effects of restructuring activities, impact of changes to U.S. GAAP, labor matters, and disruptions relating to manmade and natural disasters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2025. These forward-looking statements represent Vontier’s beliefs and assumptions only as of the date of this release and Vontier does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

Investor Relations:

Ryan Edelman

Vice President, Investor Relations

Vontier Corporation

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Trucking Automotive Technology Transport Software Artificial Intelligence Fleet Management

MEDIA:

Logo
Logo

MarketAxess Reports First Quarter 2026 Financial Results

MarketAxess Reports First Quarter 2026 Financial Results

12% Increase in Total Revenue to Record $233 Million Driven by 20% Growth in Revenue Outside U.S. Credit Products

Strong Results Reflect Heightened Demand for Our Differentiated Liquidity by Our Global Client Network

35% Increase in Block Trading ADV With Record U.S. High-Grade, U.S. High-Yield, EM and Eurobonds Block ADV

51% Increase in Portfolio Trading ADV to Record $1.9 Billion with Record U.S. Credit and EM ADV

EPS of $2.20; $2.25 Excluding Notable Items1

NEW YORK–(BUSINESS WIRE)–
MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, today announced financial results for the first quarter ended March 31, 2026.

1Q26 select financial and operational highlights*

  • Record total revenues of $233.4 million increased 12%, and included an increase of approximately $3.4 million from the impact of foreign currency fluctuations.

    12% growth in total commission revenue to record$203 million driven by record total credit (+9%) and record total rates (+29%) commission revenue.

    10% growth in services revenue2 to record$30 million.

    20% growth in revenue outside U.S. credit, including 21% growth in combined emerging markets (record) and eurobonds (record) variable transaction revenue, reflecting the strong contribution from our international products. 
  • Strong progress with our new initiatives across our three strategic channels:

    Client-Initiated Channel35% increase in block trading average daily volume (“ADV”) toa record $6.6 billion, including record U.S. credit (+27%), record emerging markets (+47%) and record eurobonds (+45%).

    Portfolio Trading Channel51% increase in total portfolio trading ADV toa record $1.9 billion with record U.S. high-grade (+36%), record U.S. high-yield (+78%) and record emerging markets (+69%) portfolio trading ADV.

    Dealer-Initiated Channel3% increase in dealer-initiated ADV to a record$1.9 billion, including 168% increase in Mid-X ADV to record levels.
  • Total expenses of $132.5 million increased 10%, and included an increase of approximately $2.2 million from the impact of foreign currency fluctuations. Total expenses, excluding notable items,1 of $130.3million increased 8%.

  • Operating margin of 43.2%, representing an increase of approximately 80 basis points; Operating margin, excluding notable items,1 of 44.2%, representing an increase of approximately 180 basis points.

  • Diluted earnings-per-share (“EPS”) of $2.20 on net income of $78.1million, compared to $0.40 and $15.1 million in the prior year,respectively; EPS of $2.25 on net income of $79.7 million, each excluding notable items,1 increased 20% and 14%, respectively.

  • Completed $300 million accelerated stock repurchase (“ASR”) agreement, which was the main driver of an approximately 6% reduction in share countcompared to the prior year,enhancing EPS growth.

*All comparisons versus 1Q25

 

 

Chris Concannon, CEO of MarketAxess, commented:

 

“We delivered record levels of trading volume, commission revenue and services revenue, driven by increased volatility and heightened demand for our differentiated liquidity from our global client network. Our strong results were broad-based and included 20% growth in revenue outside of U.S. credit, including record levels of commission revenue in emerging markets and eurobonds. Our new initiatives are also continuing to gain traction across our three strategic channels with record levels of ADV across block trading, portfolio trading and dealer-initiated activity.

Our MarketAxess advantage continued to strengthen in the first quarter by expanding our global network, deepening our differentiated liquidity and widening the competitive moat of our proprietary data and analytics. Our accelerating use of AI will help us deliver new trading and unique data solutions to our clients.”

 

Table 1: 1Q26 select financial results

 

 

Quarter

 

% Change

$ in millions, except per share data (unaudited)

 

1Q 2026

 

4Q 2025

 

1Q 2025

 

QoQ

YoY

Selected GAAP-basis financial results

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$

233

 

$

209

 

$

209

 

 

11

 

%

 

12

 

%

Expenses

 

 

132

 

 

133

 

 

120

 

 

(1

)

 

 

10

 

 

Operating margin

 

 

43.2

%

 

36.3

%

 

42.4

%

 

+690

 

bps

 

+80

 

bps

Net Income

 

 

78

 

 

92

 

 

15

 

 

(15

)

 

 

418

 

 

Diluted EPS

 

 

2.20

 

 

2.51

 

 

0.40

 

 

(12

)

 

 

450

 

 

Net Income Margin

 

 

33.5

%

 

44.1

%

 

7.2

%

NM

 

 

NM

 

 

Selected GAAP-basis financial results ex-notable

items (non-GAAP)1

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

 

233

 

 

209

 

 

209

 

 

11

 

 

 

12

 

 

Expenses

 

 

130

 

 

132

 

 

120

 

 

(2

)

 

 

8

 

 

Operating margin

 

 

44.2

%

 

36.8

%

 

42.4

%

 

+740

 

bps

 

+180

 

bps

Net Income

 

 

80

 

 

62

 

 

70

 

 

29

 

 

 

14

 

 

Diluted EPS

 

 

2.25

 

 

1.68

 

 

1.87

 

 

34

 

 

 

20

 

 

Other Non-GAAP financial measures

 

 

 

 

 

 

 

 

 

 

 

 

 

EBITDA3

 

 

122

 

 

95

 

 

107

 

 

28

 

 

 

13

 

 

EBITDA Margin3

 

 

52.1

%

 

45.3

%

 

51.5

%

 

+680

 

bps

 

+60

 

bps

NM – not meaningful

1Q26 overview of results

Table 1A: Notable items1

 

 

Quarter

 

 

 

1Q 2026

 

4Q 2025

 

1Q 2025

 

$ in millions, except per share data (unaudited)

 

 

 

 

 

 

 

Repositioning charges

 

$

1.5

 

$

1.1

 

$

 

Other notable items

 

 

0.7

 

 

 

 

 

Notable items (pre-tax)

 

 

2.2

 

 

1.1

 

 

 

Income tax impact from notable items

 

 

(0.5

)

 

(0.3

)

 

 

Reserve for uncertain tax positions related to

prior periods

 

 

 

 

(31.3

)

 

54.9

 

Total notable items

 

$

1.7

 

$

(30.5

)

$

54.9

 

EPS impact

 

$

0.05

 

$

(0.83

)

$

1.47

 

Notable items1

  • Notable items in 1Q26 include repositioning charges of $1.5 million, which consisted of severance costs related to changes in management structure, and $0.7 million of other legal expenses.

Revenue

  • Record total revenues of $233.4 million increased 12% compared to the prior year andincluded RFQ-hub revenues of approximately $4.7 million and a $3.4 million increasefrom the impact of foreign currency fluctuations.

Commission revenue

Table 1B: 1Q26 variable transaction fees per million (FPM)

 

 

Quarter

 

% Change

 

 

1Q 2026

 

4Q 2025

 

1Q 2025

 

QoQ

YoY

AVG. VARIABLE TRANS. FEE PER MILLION (FPM)

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Credit

 

$

132

 

$

138

 

$

139

 

 

(4

)

%

 

(5

)

%

Total Rates

 

 

4.68

 

 

4.79

 

 

4.20

 

 

(2

)

 

 

11

 

 

Credit

  • Record total credit commission revenue of $183.8million (including $33.4 million in fixed-distribution fees) increased $14.6 million, or 9%, compared to $169.1 million (including $33.3 million in fixed-distribution fees) in the prior year, and was up 11% from 4Q25 levels. A 17% increase in total credit ADV compared to the prior year, driven by growth in market volumes, was partially offset by a 5% decrease in total credit variable transaction fee per million (“FPM”). The 9% increase in total credit commission revenue was driven by a 21% increase in emerging markets and eurobonds commission revenue, reflecting continued product and geographic diversification. The decline in 1Q26 total credit FPM year-over-year was driven by protocol and product mix, partially offset by the higher duration of bonds traded in U.S. high-grade. The quarter-over-quarter decline was due principally to product mix.

Rates

  • Record total rates commission revenue of $9.0 million increased $2.0 million, or 29%,compared to the prior year, and increased 33% from 4Q25 levels. The increase compared to the prior year was driven by a 16% increase in total rates ADVand an 11% increase in FPM.

Other

  • Record total other commission revenue of $10.7million increased $5.5 million, or 104%,compared to the prior year, driven by the inclusion of approximately $4.3million from RFQ-hub, majority control of which was acquired in 2Q25.

Services revenue

  • Record services revenue2 of $29.9 million increased $2.7 million, or 10%, compared to the prior year.

Information services

— Information services revenue of $14.4 million increased $1.5 million, or 12%, compared to the prior year. The increase was principally driven by net new contract revenue and an increase of $0.5 million from the impact of foreign currency fluctuations.

Post-trade services

— Post-trade services revenue of $11.6 million increased $0.5 million, or 5%, compared to the prior year principally due to an increase of $1.0 million from the impact of foreign currency fluctuations.

Technology services

— Total technology services revenue of $3.9 million increased $0.6 million, or 19%, compared to the prior year.The increase was driven by connectivity feesfrom RFQ-hub, majority control of which was acquired in 2Q25.

Expenses

  • Total expenses of $132.5 million increased 10% from the prior year, including approximately $3.4 million of RFQ-hub expenses and an increase of $2.2 million from the impact of foreign currency fluctuations. Total expenses, excluding notable items,1 of $130.3 million increased 8% from the prior year.

Non-operating

  • Other income (expense): Other income was $3.0million, down from $7.8 million in the prior year. The decrease was driven by lower interest income due to a decrease in interest rates and higher interest expense due to borrowings on the Company’s credit facility that were used, along with cash on hand, to fund the ASR, partially offset by receipt of a tax credit.
  • Tax rate: The effective tax rate was 24.8%, compared to 84.3% in the prior year. The effective tax rate excluding notable items1 in the prior yearwas 27.2%.

Capital

  • The Company had $537.4 million in cash, cash equivalents, corporate bond investments and U.S. Treasury investments as of March 31, 2026, down from $678.9 million as of December 31, 2025.The Company had $157.0 million in borrowings outstanding under the Company’s credit facility as of March 31, 2026, as compared to $220.0 million in borrowings outstanding as of December 31, 2025. As of April 30, 2026, the Company had $137.0 million in borrowings outstanding under the Company’s credit facility.

  • Final settlement of the previously disclosed $300.0 million ASR occurred on February 4, 2026, with the delivery of 359,782 additional shares. As of April 30, 2026, $205.0 million remained under the Board of Directors’ share repurchase authorizations.

  • The Board declared a quarterly cash dividend of $0.78 per share, payable on June 3, 2026 to stockholders of record as of the close of business on May 20, 2026.

Other

  • Employee headcount was 859 as of March 31, 2026, down from 869 as of December 31,2025 and 870 as of March 31, 2025.

1

 

See Table 1A in this release for a listing of notable items. Results excluding notable items are non-GAAP financial measures. Refer to “Non-GAAP financial measures and other items” for a discussion of these non-GAAP financial measures and Table 6 for a reconciliation of these non-GAAP financial measures to their most directly comparable GAAP measures.

2

 

Services revenue is defined as combined information, post-trade and technology services revenue.

3

 

EBITDA and EBITDA margin are non-GAAP financial measures. Refer to “Non-GAAP financial measures and other items” for a discussion of these non-GAAP financial measures and Table 7 for a reconciliation of these non-GAAP financial measures to their most directly comparable GAAP measures.

Non-GAAP financial measures and other items

To supplement the Company’s unaudited financial statements presented in accordance with generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures, including earnings before interest, taxes, depreciation and amortization (“EBITDA”), EBITDA margin and free cash flow. From time to time, we present selected GAAP-basis financial results, excluding notable items. Notable items are revenues, expenses, other income (expense) and tax related items that are non-recurring and outside of the Company’s normal course of business or other notables, such as acquisition and restructuring charges or gains/losses on sales (collectively, “notable items”). We define EBITDA margin as EBITDA divided by revenues. We define free cash flow as net cash provided by/(used in) operating activities excluding the net change in trading investments and net change in securities failed-to-deliver and securities failed-to-receive from broker-dealers, clearing organizations and customers, less expenditures for furniture, equipment and leasehold improvements and capitalized software development costs. Non-GAAP financial measures should be considered in addition to, not as a substitute for or superior to, financial measures determined in conformity with GAAP. The Company believes that these non-GAAP financial measures, when taken into consideration with the corresponding GAAP financial measures, provide additional information regarding the Company’s operating results because they assist both investors and management in analyzing and evaluating the performance of our business. Please refer to Tables 6, 7 & 8 for a reconciliation of: (i) selected GAAP-basis financial results, each excluding notable items, to their most directly comparable GAAP measure; (ii) GAAP net income to EBITDA and GAAP net income margin to EBITDA margin; and (iii) GAAP net cash provided by/(used in) operating activities to free cash flow, in each case, the most directly comparable GAAP measure.

Webcast and conference call information

Chris Concannon, Chief Executive Officer and Ilene Fiszel Bieler, Chief Financial Officer, will host a conference call to discuss the Company’s financial results and outlook on Thursday, May 7, 2026 at 10:00 a.m. ET. To access the conference call, please dial +1-800-715-9871 (U.S.) or +1-646-307-1963 (International) and use the ID 1832176. The Company will also host a live audio Webcast of the conference call on the Investor Relations section of the Company’s website at http://investor.marketaxess.com. The Webcast will be archived on http://investor.marketaxess.com for 90 days following the announcement.

General Notes Regarding the Data Presented

Reported MarketAxess volume in all product categories includes only fully electronic trading volume. MarketAxess trading volumes and the Financial Industry Regulatory Authority (“FINRA”) Trade Reporting and Compliance Engine (“TRACE”) reported volumes are available on the Company’s website at investor.marketaxess.com/volume.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including statements about the outlook and prospects for the Company, market conditions and industry growth, as well as statements about the Company’s future financial and operating performance. These and other statements that relate to future results and events are based on MarketAxess’ current expectations. The Company’s actual results in future periods may differ materially from those currently expected or desired because of a number of risks and uncertainties, including: global economic, political and market factors; the level of trading volume transacted on the MarketAxess platform; the rapidly evolving nature of the electronic financial services industry; the level and intensity of competition in the fixed-income electronic trading industry and the pricing pressures that may result; the variability of our growth rate; our ability to introduce new fee plans and our clients’ response; our ability to attract clients or adapt our technology and marketing strategy to new markets; risks related to our growing international operations; our dependence on our broker-dealer clients; the loss of any of our significant institutional investor clients; our exposure to risks resulting from non-performance by counterparties to transactions executed between our clients in which we act as an intermediary in matched principal trades; risks related to self-clearing; our dependence on third-party suppliers for key products and services; our ability to enter into strategic alliances and to acquire other businesses and successfully integrate them with our business; our dependence on our management team and our ability to attract and retain talent; risks related to sanctions levied against states or individuals that could expose us to operational or regulatory risks; the effects of climate change or other sustainability risks that could affect our operations or reputation; the effect of rapid market or technological changes on us and the users of our technology; issues related to the development and use of artificial intelligence; our ability to successfully maintain the integrity of our trading platform and our response to system failures, capacity constraints and business interruptions; the occurrence of design defects, errors, failures or delays with our platforms, products or services; our vulnerability to malicious cyber-attacks and attempted cybersecurity breaches; our actual or perceived failure to comply with privacy and data protection laws; our ability to protect our intellectual property rights or technology and defend against intellectual property infringement or other claims; our use of open-source software; limitations on our flexibility because we operate in a highly regulated industry; the increasing government regulation of us and our clients; our exposure to costs and penalties related to our extensive regulation; our risks of litigation and securities laws liability; our tax filing positions; our future capital needs and our ability to obtain capital when needed; limitations on our operating flexibility contained in our credit agreement; our exposure to financial institutions by holding cash in excess of federally insured limits; and other factors. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. More information about these and other factors affecting MarketAxess’ business and prospects is contained in MarketAxess’ periodic filings with the Securities and Exchange Commission and can be accessed at www.marketaxess.com.

About MarketAxess

MarketAxess (Nasdaq: MKTX) operates a leading electronic trading platform that delivers greater trading efficiency, a diversified pool of liquidity and significant cost savings to institutional investors and broker-dealers across the global fixed-income and other markets. Approximately 2,100 firms leverage MarketAxess’ patented technology to efficiently trade fixed-income securities. Our automated and algorithmic trading solutions, combined with our integrated and actionable data offerings, help our clients make faster, better-informed decisions on when and how to trade on our platform. MarketAxess’ award-winning Open Trading® marketplace is widely regarded as the preferred all-to-all trading solution in the global credit markets. Founded in 2000, MarketAxess connects a robust network of market participants through an advanced full trading lifecycle solution that includes automated trading solutions, intelligent data and index products and a range of post-trade services. Learn more at www.marketaxess.com and on X @MarketAxess.

Table 2: Consolidated Statements of Operations

 

 

 

Three Months Ended

 

 

 

 

 

March 31,

 

 

In thousands, except per share data (unaudited)

 

 

2026

 

 

2025

 

 

% Change

Revenues

 

 

 

 

 

Commissions

 

 

$

203,471

 

 

$

181,343

 

 

 

12

 

%

Information services

 

 

 

14,445

 

 

 

12,904

 

 

 

12

 

 

Post-trade services

 

 

 

11,607

 

 

 

11,088

 

 

 

5

 

 

Technology services

 

 

 

3,857

 

 

 

3,241

 

 

 

19

 

 

Total revenues

 

 

 

233,380

 

 

 

208,576

 

 

 

12

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

 

 

Employee compensation and benefits

 

 

 

70,195

 

 

 

61,916

 

 

 

13

 

 

Depreciation and amortization

 

 

 

19,210

 

 

 

18,236

 

 

 

5

 

 

Technology and communications

 

 

 

20,360

 

 

 

18,048

 

 

 

13

 

 

Professional and consulting fees

 

 

 

6,376

 

 

 

6,410

 

 

 

(1

)

 

Occupancy

 

 

 

3,819

 

 

 

3,622

 

 

 

5

 

 

Marketing and advertising

 

 

 

2,334

 

 

 

2,061

 

 

 

13

 

 

Clearing costs

 

 

 

4,426

 

 

 

4,185

 

 

 

6

 

 

General and administrative

 

 

 

5,739

 

 

 

5,716

 

 

 

 

 

Total expenses

 

 

 

132,459

 

 

 

120,194

 

 

 

10

 

 

Operating income

 

 

 

100,921

 

 

 

88,382

 

 

 

14

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

 

4,308

 

 

 

7,169

 

 

 

(40

)

 

Interest expense

 

 

 

(2,888

)

 

 

(213

)

 

NM

 

 

Equity in earnings of

unconsolidated affiliate

 

 

 

 

 

 

289

 

 

 

(100

)

 

Other, net

 

 

 

1,544

 

 

 

527

 

 

 

193

 

 

Total other income (expense)

 

 

 

2,964

 

 

 

7,772

 

 

 

(62

)

 

Income before income taxes

 

 

 

103,885

 

 

 

96,154

 

 

 

8

 

 

Provision for income taxes

 

 

 

25,778

 

 

 

81,089

 

 

 

(68

)

 

Net income

 

 

$

78,107

 

 

$

15,065

 

 

 

418

 

 

Less: income attributable to

noncontrolling interest

 

 

 

(225

)

 

 

 

 

NM

 

 

Net income available for common

stockholders

 

 

$

77,882

 

 

$

15,065

 

 

 

417

 

 

Per Share Data:

 

 

 

 

 

 

 

 

 

 

 

Net income per common share

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

$

2.21

 

 

$

0.40

 

 

 

 

 

Diluted

 

 

$

2.20

 

 

$

0.40

 

 

 

 

 

Cash dividends declared per

common share

 

 

$

0.78

 

 

$

0.76

 

 

 

 

 

Weighted-average common shares:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

35,301

 

 

 

37,388

 

 

 

 

 

Diluted

 

 

 

35,386

 

 

 

37,456

 

 

 

 

 

NM – not meaningful

Table 3: Commission Revenue Detail

Table 3: Commission Revenue Detail

In thousands, except fee per million data

 

 

Three Months Ended March 31,

 

 

(unaudited)

 

 

2026

 

 

2025

 

 

% Change

 

 

Variable transaction fees

 

 

 

 

 

 

 

 

 

 

 

Credit

 

 

$

150,347

 

 

$

135,840

 

 

 

11

 

%

Rates

 

 

 

8,922

 

 

 

6,919

 

 

 

29

 

 

Other

 

 

 

10,697

 

 

 

5,232

 

 

 

104

 

 

Total variable transaction fees

 

 

 

169,966

 

 

 

147,991

 

 

 

15

 

 

Fixed distribution fees

 

 

 

 

 

 

 

 

 

 

 

Credit

 

 

 

33,403

 

 

 

33,265

 

 

 

 

 

Rates

 

 

 

102

 

 

 

87

 

 

 

17

 

 

Total fixed distribution fees

 

 

 

33,505

 

 

 

33,352

 

 

 

 

 

Total commission revenue

 

 

$

203,471

 

 

$

181,343

 

 

 

12

 

 

Average variable transaction fee

per million

 

 

 

 

 

 

 

 

 

 

 

Credit

 

 

$

132

 

 

$

139

 

 

 

(5

)

%

Rates

 

 

 

4.68

 

 

 

4.20

 

 

 

11

 

 

Table 4: Trading Volume Detail*

 

 

 

Three Months Ended March 31,

 

 

In millions (unaudited)

 

 

2026

 

 

2025

 

 

% Change

 

 

 

 

 

Volume

 

 

ADV

 

 

Volume

 

 

 

ADV

 

 

Volume

 

 

 

ADV

 

 

Credit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

High-grade

 

 

$

511,492

 

 

$

8,385

 

 

$

461,308

 

 

 

$

7,562

 

 

 

11

 

%

 

 

11

 

%

High-yield

 

 

 

100,409

 

 

 

1,646

 

 

 

89,997

 

 

 

 

1,475

 

 

 

12

 

 

 

 

12

 

 

Emerging markets

 

 

 

311,925

 

 

 

5,114

 

 

 

240,285

 

 

 

 

3,939

 

 

 

30

 

 

 

 

30

 

 

Eurobonds

 

 

 

178,162

 

 

 

2,828

 

 

 

147,917

 

 

 

 

2,348

 

 

 

20

 

 

 

 

20

 

 

Other credit

 

 

 

40,186

 

 

 

659

 

 

 

36,482

 

 

 

 

598

 

 

 

10

 

 

 

 

10

 

 

Total credit trading

 

 

 

1,142,174

 

 

 

18,632

 

 

 

975,989

 

 

 

 

15,922

 

 

 

17

 

 

 

 

17

 

 

Rates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. government bonds

 

 

 

1,800,150

 

 

 

29,511

 

 

 

1,582,081

 

 

 

 

25,936

 

 

 

14

 

 

 

 

14

 

 

Agency and other government bonds

 

 

 

104,376

 

 

 

1,659

 

 

 

65,825

 

 

 

 

1,047

 

 

 

59

 

 

 

 

58

 

 

Total rates trading

 

 

 

1,904,526

 

 

 

31,170

 

 

 

1,647,906

 

 

 

 

26,983

 

 

 

16

 

 

 

 

16

 

 

Total trading

 

 

$

3,046,700

 

 

$

49,802

 

 

$

2,623,895

 

 

 

$

42,905

 

 

 

16

 

 

 

 

16

 

 

Number of U.S. Trading Days1

 

 

 

 

 

 

61

 

 

 

 

 

 

 

61

 

 

 

 

 

 

 

 

 

Number of U.K. Trading Days2

 

 

 

 

 

 

63

 

 

 

 

 

 

 

63

 

 

 

 

 

 

 

 

 

1 The number of U.S. trading days is based on the SIFMA holiday recommendation calendar.

2 The number of U.K. trading days is based on the U.K. Bank holiday schedule.

* Consistent with FINRA TRACE reporting standards, both sides of trades are included in the Company’s reported volumes when the Company executes trades on a matched principal basis between two counterparties. Consistent with industry standards, U.S. government bond trades are single-counted.

Table 5: Consolidated Condensed Balance Sheet Data

 

 

As of

 

 

In thousands (unaudited)

 

March 31, 2026

 

 

December 31, 2025

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

377,302

 

 

$

519,734

 

 

Cash segregated under federal regulations

 

 

49,053

 

 

 

48,722

 

 

Investments, at fair value

 

 

170,808

 

 

 

170,677

 

 

Accounts receivable, net

 

 

128,171

 

 

 

100,989

 

 

Receivables from broker-dealers, clearing organizations and customers, including

$75,072 pledged as collateral as of March 31, 2026

 

 

977,049

 

 

 

489,211

 

 

Goodwill

 

 

283,667

 

 

 

283,667

 

 

Intangible assets, net of accumulated amortization

 

 

105,281

 

 

 

110,629

 

 

Furniture, equipment, leasehold improvements and

capitalized software, net

 

 

111,642

 

 

 

112,431

 

 

Operating lease right-of-use assets

 

 

50,986

 

 

 

51,854

 

 

Prepaid expenses and other assets

 

 

47,577

 

 

 

46,972

 

 

Total assets

 

$

2,301,536

 

 

$

1,934,886

 

 

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

Accrued employee compensation

 

$

34,738

 

 

$

73,879

 

 

Payables to broker-dealers, clearing organizations and customers

 

 

696,302

 

 

 

325,959

 

 

Borrowings

 

 

228,250

 

 

 

220,000

 

 

Income and other tax liabilities

 

 

35,503

 

 

 

49,267

 

 

Accounts payable, accrued expenses and other liabilities

 

 

39,115

 

 

 

42,584

 

 

Operating lease liabilities

 

 

63,711

 

 

 

64,938

 

 

Total liabilities

 

 

1,097,619

 

 

 

776,627

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interest

 

 

13,520

 

 

 

12,592

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity

 

 

 

 

 

 

 

Common stock

 

 

124

 

 

 

123

 

 

Additional paid-in capital

 

 

365,428

 

 

 

305,923

 

 

Treasury stock

 

 

(752,333

)

 

 

(694,764

)

 

Retained earnings

 

 

1,588,852

 

 

 

1,538,746

 

 

Accumulated other comprehensive income/(loss)

 

 

(11,674

)

 

 

(4,361

)

 

Total stockholders’ equity

 

 

1,190,397

 

 

 

1,145,667

 

 

Total liabilities, redeemable noncontrolling interest

and stockholders’ equity

 

$

2,301,536

 

 

$

1,934,886

 

 

 

 

 

 

 

 

 

 

Table 6: Reconciliation of Notable Items

 

Quarter

 

$ in thousands, except per share data (unaudited)

 

1Q 2026

 

 

4Q 2025

 

 

1Q 2025

 

 

 

 

 

 

 

 

 

 

 

Total Expenses, GAAP-basis

 

$

132,459

 

 

$

133,396

 

 

$

120,194

 

Exclude: Notable items

 

 

 

 

 

 

 

 

 

Repositioning charges1

 

 

(1,484

)

 

 

(1,084

)

 

 

 

Other notable items2

 

 

(656

)

 

 

 

 

 

 

Total Expenses, excluding notable items

 

$

130,319

 

 

$

132,312

 

 

$

120,194

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income, GAAP-basis

 

$

78,107

 

 

$

92,394

 

 

$

15,065

 

Exclude: Notable items

 

 

 

 

 

 

 

 

 

Repositioning charges1

 

 

1,484

 

 

 

1,084

 

 

 

 

Other notable items2

 

 

656

 

 

 

 

 

 

 

Income tax impact from notable items

 

 

(531

)

 

 

(254

)

 

 

 

Reserve for uncertain tax positions

related to prior periods

 

 

 

 

 

(31,308

)

 

 

54,939

 

Net income, excluding notable items

 

$

79,716

 

 

$

61,916

 

 

$

70,004

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating margin, GAAP-basis

 

 

43.2

%

 

 

36.3

%

 

 

42.4

%

Notable items as reconciled above

 

 

1.0

 

 

 

0.5

 

 

 

 

Operating margin, excluding notable items

 

 

44.2

%

 

 

36.8

%

 

 

42.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted EPS, GAAP-basis

 

$

2.20

 

 

$

2.51

 

 

$

0.40

 

Notable items as reconciled above

 

 

0.05

 

 

 

(0.83

)

 

 

1.47

 

Diluted EPS, excluding notable items

 

$

2.25

 

 

$

1.68

 

 

$

1.87

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effective tax rate, GAAP-basis

 

 

24.8

%

 

 

-15.8

%

 

 

84.3

%

Notable items as reconciled above

 

 

 

 

 

39.2

 

 

 

(57.1

)

Effective tax rate, excluding notable

items

 

 

24.8

%

 

 

23.4

%

 

 

27.2

%

1

Repositioning charges consist of severance included in employee compensation and benefits

2

Consists of legal expenses included in professional and consulting

Table 7: Reconciliation of Net Income to EBITDA and Net Income Margin to EBITDA Margin

 

 

Quarter

In thousands (unaudited)

 

 

1Q 2026

 

 

4Q 2025

 

 

1Q 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

$

78,107

 

 

$

92,394

 

 

$

15,065

 

 

Add back:

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

 

(4,308

)

 

 

(5,448

)

 

 

(7,169

)

 

Interest expense

 

 

 

2,888

 

 

 

964

 

 

 

213

 

 

Provision for income taxes

 

 

 

25,778

 

 

 

(12,608

)

 

 

81,089

 

 

Depreciation and amortization

 

 

 

19,210

 

 

 

19,606

 

 

 

18,236

 

 

EBITDA

 

 

$

121,675

 

 

$

94,908

 

 

$

107,434

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income margin1

 

 

 

33.5

%

 

 

44.1

%

 

 

7.2

%

 

Add back:

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

 

(1.8

)

 

 

(2.6

)

 

 

(3.4

)

 

Interest expense

 

 

 

1.2

 

 

 

0.5

 

 

 

0.1

 

 

Provision for income taxes

 

 

 

11.0

 

 

 

(6.1

)

 

 

38.9

 

 

Depreciation and amortization

 

 

 

8.2

 

 

 

9.4

 

 

 

8.7

 

 

EBITDA margin2

 

 

 

52.1

%

 

 

45.3

%

 

 

51.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

1

Net income margin is derived by dividing net income by total revenues for the applicable period.

2

EBITDA margin is derived by dividing EBITDA by total revenues for the applicable period.

Table 8: Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow

 

 

Quarter

In thousands (unaudited)

 

 

1Q 2026

 

 

4Q 2025

 

 

1Q 2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used in)/provided by operating activities

 

 

$

(75,329

)

 

$

158,632

 

 

$

29,629

 

 

Exclude: Net change in trading

investments

 

 

 

 

 

 

(404

)

 

 

 

 

Exclude: Net change in fail-to-deliver/receive

from broker-dealers, clearing organizations

and customers

 

 

 

108,529

 

 

 

(67,825

)

 

 

34,399

 

 

Less: Purchases of furniture, equipment

and leasehold improvements

 

 

 

(259

)

 

 

(3,572

)

 

 

(1,930

)

 

Less: Capitalization of software

development costs

 

 

 

(17,089

)

 

 

(11,775

)

 

 

(15,031

)

 

Free cash flow

 

 

$

15,852

 

 

$

75,056

 

 

$

47,067

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

INVESTOR RELATIONS

Stephen Davidson

MarketAxess Holdings Inc.

+1 212 813 6313

[email protected]

MEDIA RELATIONS

Marisha Mistry

MarketAxess Holdings Inc.

+1 917 267 1232

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Fintech Other Professional Services Professional Services Finance

MEDIA:

Logo
Logo

Maximus Reports Fiscal Year 2026 Second Quarter Results

Maximus Reports Fiscal Year 2026 Second Quarter Results

Raises earnings outlook and announces $400 million share repurchase program

TYSONS, Va.–(BUSINESS WIRE)–Maximus (NYSE: MMS), a leading provider of government services, reported financial results for the three and six months ended March 31, 2026.

Highlights for the second quarter of fiscal year 2026 include:

  • Revenue of $1.31 billion was consistent with our full fiscal year 2026 expectations, and compares to $1.36 billion for the prior year period.

  • Diluted earnings per share were $1.80 and adjusted diluted earnings per share were $2.07, compared to $1.69 and $2.01, respectively, for the prior year period.

  • We are raising our adjusted EBITDA margin expectation by 20 basis points to approximately 14.2% and raising our adjusted diluted earnings per share expectation by $0.20 to range between $8.25 and $8.55 per share for the full fiscal year 2026. We are reiterating previous fiscal year 2026 revenue and free cash flow guidance.

  • Repurchases of Maximus common stock in the quarter totaled 1.4 million shares for $111 million, with an additional 0.6 million shares totaling $39.9 million repurchased through May 1, 2026.

  • The Board of Directors authorized a refresh to the repurchase program for Maximus common stock up to an aggregate of $400 million.

  • A quarterly cash dividend of $0.33 per share is payable on June 1, 2026, to shareholders of record on May 15, 2026.

“Our second consecutive earnings guidance increase reflects growing confidence in our ability to leverage in-house AI and other technology capabilities to improve efficiency and support margin expansion. We continue to execute our capital deployment strategy, as highlighted by the refresh of our share repurchase authorization up to an aggregate of $400 million,” said Bruce Caswell, President and Chief Executive Officer.

Caswell continued, “Our state customers are gaining clarity and beginning to take action to help address challenges with Medicaid community engagement, SNAP administration, and unemployment insurance support services. We’re pleased to be playing a role in devising these solutions and expect momentum to continue to build.”

Second Quarter Results

Revenue for the second quarter of fiscal year 2026 was $1.31 billion and on track with full fiscal year 2026 expectations. Prior year period revenue was $1.36 billion and benefited from natural disaster support work and temporary clinical volume surges in both domestic segments.

For the second quarter of fiscal year 2026, operating margin was 11.4% and adjusted EBITDA margin was 14.4%. This compares to margins of 11.2% and 13.7%, respectively, for the prior year period. Diluted earnings per share were $1.80, and adjusted diluted earnings per share were $2.07. This compares to $1.69 and $2.01, respectively, for the prior year period.

Consolidated earnings improved over the prior year period primarily due to efficiency gains through automation, including AI-enabled tools, across multiple program areas. The second quarter of fiscal year 2026 included a non-cash impairment charge that decreased the U.S. Services segment’s operating income by $6.9 million, or $0.09 per share, and a discrete research & development tax benefit that reduced the income tax expense by $4.2 million, which equated to a $0.08 per share benefit. Both non-recurring items were excluded from adjusted EBITDA and had offsetting impacts on adjusted diluted earnings per share.

U.S. Federal Services Segment

U.S. Federal Services Segment revenue for the second quarter of fiscal year 2026 was $753 million. Prior year period revenue was $778 million and benefited from natural disaster support. We anticipated the absence of this work in our fiscal year 2026 guidance, and, excluding this support work, segment organic revenue growth was 1.5% over the prior year period.

The segment operating margin for the second quarter of fiscal year 2026 was 17.6%, compared to 15.3% reported for the prior year period. Technology initiatives, including automation that enables greater volume processing without a commensurate increase in labor costs, were the primary driver of the improved margin and the increase to the segment’s full fiscal year margin expectation. The full fiscal year 2026 operating margin for the U.S. Federal Services Segment is expected to be approximately 17.5%.

U.S. Services Segment

U.S. Services Segment revenue for the second quarter of fiscal year 2026 was $416 million and on track to improve segment revenue growth anticipated by the end of the fiscal year. The prior year period segment revenue was $442 million.

The segment operating margin for the second quarter of fiscal year 2026 was 9.3%, or 10.9% excluding the $6.9 million non-cash charge related to an asset impairment. The prior year period segment operating margin was 12.2%. The full fiscal year 2026 operating margin for the U.S. Services Segment is expected to be approximately 10.0% as a result of the non-cash charge this quarter.

Outside the U.S. Segment

Outside the U.S. Segment revenue for the second quarter of fiscal year 2026 was $137 million, compared to $142 million in the prior year period. Following previous reshaping actions, the segment now comprises the United Kingdom, Canada, and the Gulf Region, all of which are tracking opportunities that we believe have the potential to drive future growth.

The segment realized an operating loss of $3.1 million for the second quarter of fiscal year 2026, compared to an operating profit of $4.8 million in the prior year period. We continue to anticipate future margin improvement over time in this segment, which is now expected to break even on a full fiscal year 2026 basis.

Sales and Pipeline

Year-to-date signed contract awards at March 31, 2026, totaled $913 million, and contracts pending (awarded but unsigned) totaled $322 million.

The sales pipeline at March 31, 2026, totaled $56.8 billion, comprised of approximately $4.55 billion in proposals pending, $1.48 billion in proposals in preparation, and $50.7 billion in opportunities we are tracking. New work opportunities represent approximately 59% of the total sales pipeline, and U.S. Federal Services Segment opportunities represent approximately 58% of the total sales pipeline.

Balance Sheet and Cash Flows

At March 31, 2026, unrestricted cash and cash equivalents totaled $157 million, and gross debt was $1.55 billion. The ratio of debt, net of allowed cash, to consolidated EBITDA for the quarter ended March 31, 2026, as calculated on a trailing twelve-month basis in accordance with our credit agreement, was 1.8x. This is unchanged from the ratio at December 31, 2025, and remains below our target net leverage ratio of 2x to 3x.

For the second quarter of fiscal year 2026, cash provided by operating activities totaled $190 million, and free cash flow was $179 million. DSO were 78 days at March 31, 2026, and unchanged from the DSO at December 31, 2025. We expect collections to increase in the second half of fiscal year 2026, which supports our full-year free cash flow guidance.

During the second quarter of fiscal year 2026, we purchased approximately 1.4 million shares of Maximus common stock totaling $111 million. Subsequent to March 31, 2026, and through May 1, 2026, we purchased an additional 0.6 million shares totaling $39.9 million. The Board of Directors authorized a refresh to the repurchase program for Maximus common stock up to an aggregate of $400 million, which becomes effective May 11, 2026.

On April 6, 2026, our Board of Directors declared a quarterly cash dividend of $0.33 for each share of our common stock outstanding. The dividend is payable on June 1, 2026, to shareholders of record on May 15, 2026.

Fiscal Year 2026 Earnings Guidance Raise

Maximus is raising fiscal year 2026 earnings guidance and reiterating revenue and free cash flow guidance.

The full year adjusted EBITDA margin guidance improves by 20 basis points to approximately 14.2%, as compared to prior guidance. Guidance for adjusted diluted earnings per share increases by $0.20 and is now expected to range between $8.25 and $8.55 per share for fiscal year 2026.

Revenue guidance is maintained between $5.2 billion and $5.35 billion, and free cash flow guidance is maintained between $450 million and $500 million for fiscal year 2026. Interest expense is estimated to be $84 million, and the full fiscal year tax rate is expected to range between 24.0% and 25.0% for fiscal year 2026.

Conference Call and Webcast Information

Maximus will host a conference call this morning, May 7, 2026, at 9:00 a.m. ET.

The call is open to the public and available by webcast or by phone at:

877.407.8289 (Domestic) / +1.201.689.8341 (International)

For those unable to listen to the live call, a recording of the webcast will be available on investor.maximus.com.

About Maximus

As a leading strategic partner to government, Maximus helps improve the delivery of public services amid complex technology, health, economic, and social challenges. With a deep understanding of program service delivery, acute insights that achieve operational excellence, and an extensive awareness of the needs of the people being served, our employees advance the critical missions of our partners. Maximus provides tech-enabled services to government agencies, including innovative business process management and technology solutions, that provide improved outcomes for the public and higher levels of productivity and efficiency of government-sponsored programs. For more information, visit maximus.com.

Non-GAAP Measures and Forward-Looking Statements

This release contains non-GAAP measures and other indicators, including organic growth, free cash flow, diluted EPS adjusted for amortization of intangible assets and divestiture-related charges and gains, adjusted EBITDA, adjusted EBITDA margin, consolidated EBITDA (as defined by our Credit Agreement), and other non-GAAP measures.

A description of these non-GAAP measures and details as to how they are calculated are included with our earnings presentation and forthcoming Form 10-Q.

The presentation of these non-GAAP numbers is not meant to be considered in isolation, nor as alternatives to cash flows from operations, revenue growth, operating income, or net income as measures of performance. These non-GAAP financial measures, as determined and presented by us, may not be comparable to related or similarly titled measures presented by other companies.

Included in this release are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “on track,” “opportunity,” “could,” “potential,” “believe,” “project,” “estimate,” “expect,” “continue,” “forecast,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similar references to future periods. Forward-looking statements that are not historical facts, including statements about our confidence, strategies and initiatives, guidance and expectations about revenues, results of operations, profitability, future contracts, liquidity, market opportunities, market demand, acceptance of our products and service offerings, or acquisitions and divestitures, are forward-looking statements that involve risks and uncertainties.

These risks could cause our actual results to differ materially from those indicated by such forward-looking statements. A summary of risk factors can be found in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed on November 20, 2025, and subsequent filings with the Securities and Exchange Commission (SEC). Our SEC filings are accessible on maximus.com.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update the guidance herein or any other forward-looking statement as circumstances evolve.

 

FY26 Guidance Reconciliation – Non-GAAP

($ in millions except per share items)

Low End

 

High End

Net income

$

394

 

 

$

411

 

Add: Interest expense / Other (income)

 

84

 

 

 

84

 

Add: Provision for income taxes

 

128

 

 

 

133

 

Add: Amortization of intangible assets

 

81

 

 

 

81

 

Add: Depreciation & amortization of property, equipment and capitalized software

 

54

 

 

 

54

 

Add: Capitalized software impairment charges

 

7

 

 

 

7

 

Add: Divestiture-related gains

 

(9

)

 

 

(9

)

Adjusted EBITDA

$

739

 

 

$

761

 

Revenue

$

5,200

 

 

$

5,350

 

 

 

 

 

Net income margin

 

7.6

%

 

 

7.7

%

Adjusted EBITDA margin

 

14.2

%

 

 

14.2

%

 

 

 

 

Diluted EPS

$

7.27

 

 

$

7.57

 

Add: effect of amortization of intangible assets on diluted EPS

 

1.10

 

 

 

1.10

 

Add: effect of divestiture-related gains on diluted EPS

 

(0.12

)

 

 

(0.12

)

Adjusted diluted EPS

$

8.25

 

 

$

8.55

 

 

 

 

 

Cash flows from operating activities

$

485

 

 

$

535

 

Remove: purchases of property and equipment and capitalized software costs

 

(35

)

 

 

(35

)

Free cash flow

$

450

 

 

$

500

 

Maximus, Inc.

Consolidated Statements of Operations

(Unaudited)

 

For the Three Months Ended

 

For the Six Months Ended

 

March 31, 2026

 

March 31, 2025

 

March 31, 2026

 

March 31, 2025

 

(in thousands, except per share amounts)

Revenue

$

1,305,967

 

 

$

1,361,786

 

 

$

2,651,013

 

 

$

2,764,461

 

Cost of revenue

 

963,703

 

 

 

1,022,965

 

 

 

1,990,079

 

 

 

2,124,083

 

Gross profit

 

342,264

 

 

 

338,821

 

 

 

660,934

 

 

 

640,378

 

Selling, general, and administrative expenses

 

173,479

 

 

 

162,857

 

 

 

325,639

 

 

 

354,592

 

Amortization of intangible assets

 

20,298

 

 

 

22,996

 

 

 

40,598

 

 

 

46,031

 

Operating income

 

148,487

 

 

 

152,968

 

 

 

294,697

 

 

 

239,755

 

Interest expense

 

22,111

 

 

 

21,469

 

 

 

42,927

 

 

 

38,991

 

Other (income)/expense, net

 

(158

)

 

 

(963

)

 

 

(1,031

)

 

 

(651

)

Income before income taxes

 

126,534

 

 

 

132,462

 

 

 

252,801

 

 

 

201,415

 

Provision for income taxes

 

28,471

 

 

 

35,893

 

 

 

60,795

 

 

 

63,650

 

Net income

$

98,063

 

 

$

96,569

 

 

$

192,006

 

 

$

137,765

 

 

 

 

 

 

 

 

 

Earnings per share:

 

 

 

 

 

 

 

Basic

$

1.81

 

 

$

1.70

 

 

$

3.52

 

 

$

2.36

 

Diluted

$

1.80

 

 

$

1.69

 

 

$

3.50

 

 

$

2.35

 

Weighted average shares outstanding:

 

 

 

 

 

 

 

Basic

 

54,242

 

 

 

56,892

 

 

 

54,547

 

 

 

58,330

 

Diluted

 

54,585

 

 

 

57,057

 

 

 

54,925

 

 

 

58,553

 

 

 

 

 

 

 

 

 

Dividends declared per share

$

0.33

 

 

$

0.30

 

 

$

0.63

 

 

$

0.60

 

Maximus, Inc.

Consolidated Balance Sheets

 

March 31, 2026

 

September 30, 2025

 

(unaudited)

 

 

 

(in thousands)

Assets:

 

 

 

Cash and cash equivalents

$

157,452

 

 

$

222,351

 

Accounts receivable, net

 

1,114,960

 

 

 

898,095

 

Income taxes receivable

 

64,792

 

 

 

3,904

 

Prepaid expenses and other current assets

 

171,644

 

 

 

128,574

 

Total current assets

 

1,508,848

 

 

 

1,252,924

 

Property and equipment, net

 

27,178

 

 

 

30,972

 

Capitalized software, net

 

202,583

 

 

 

214,260

 

Operating lease right-of-use assets

 

84,097

 

 

 

100,514

 

Goodwill

 

1,780,507

 

 

 

1,782,095

 

Intangible assets, net

 

497,342

 

 

 

538,266

 

Deferred contract costs, net

 

62,737

 

 

 

63,332

 

Deferred compensation plan assets

 

58,472

 

 

 

63,272

 

Deferred income taxes

 

7,590

 

 

 

11,491

 

Other assets

 

9,820

 

 

 

12,513

 

Total assets

$

4,239,174

 

 

$

4,069,639

 

Liabilities and Shareholders’ Equity:

 

 

 

Liabilities:

 

 

 

Accounts payable and accrued liabilities

$

281,984

 

 

$

296,888

 

Accrued compensation and benefits

 

152,362

 

 

 

236,948

 

Deferred revenue, current portion

 

37,910

 

 

 

53,784

 

Income taxes payable

 

959

 

 

 

17,321

 

Long-term debt, current portion

 

63,930

 

 

 

52,680

 

Operating lease liabilities, current portion

 

35,400

 

 

 

38,605

 

Other current liabilities

 

109,142

 

 

 

68,937

 

Total current liabilities

 

681,687

 

 

 

765,163

 

Deferred revenue, non-current portion

 

37,662

 

 

 

43,757

 

Deferred income taxes

 

212,703

 

 

 

149,020

 

Long-term debt, non-current portion

 

1,471,816

 

 

 

1,281,593

 

Deferred compensation plan liabilities, non-current portion

 

58,171

 

 

 

62,145

 

Operating lease liabilities, non-current portion

 

56,640

 

 

 

71,289

 

Other liabilities

 

23,534

 

 

 

22,637

 

Total liabilities

 

2,542,213

 

 

 

2,395,604

 

Shareholders’ equity:

 

 

 

Common stock, no par value; 100,000 shares authorized; 53,110 and 54,805

shares issued and outstanding as of March 31, 2026, and September 30, 2025,

respectively

 

639,269

 

 

 

628,118

 

Accumulated other comprehensive loss

 

(21,055

)

 

 

(17,867

)

Retained earnings

 

1,078,747

 

 

 

1,063,784

 

Total shareholders’ equity

 

1,696,961

 

 

 

1,674,035

 

Total liabilities and shareholders’ equity

$

4,239,174

 

 

$

4,069,639

 

Maximus, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

For the Three Months Ended

 

For the Six Months Ended

 

March 31, 2026

 

March 31, 2025

 

March 31, 2026

 

March 31, 2025

 

(in thousands)

Cash flows from operating activities:

 

 

 

 

 

 

 

Net income

$

98,063

 

 

$

96,569

 

 

$

192,006

 

 

$

137,765

 

Adjustments to reconcile net income to cash flows from operations:

 

 

 

 

 

 

 

Depreciation and amortization of property, equipment, and capitalized software

 

12,328

 

 

 

9,440

 

 

 

25,217

 

 

 

17,895

 

Capitalized software impairment charges

 

6,914

 

 

 

 

 

 

6,914

 

 

 

 

Amortization of intangible assets

 

20,298

 

 

 

22,996

 

 

 

40,598

 

 

 

46,031

 

Amortization of debt issuance costs and debt discount

 

736

 

 

 

672

 

 

 

1,472

 

 

 

1,310

 

Deferred income taxes

 

39,917

 

 

 

(2,747

)

 

 

67,781

 

 

 

(590

)

Stock compensation expense

 

9,899

 

 

 

12,623

 

 

 

16,918

 

 

 

19,575

 

Divestiture-related charges/(gains)

 

 

 

 

1,002

 

 

 

(8,985

)

 

 

39,343

 

Change in assets and liabilities, net of effects of business combinations and divestitures:

 

 

 

 

 

 

 

Accounts receivable

 

30,710

 

 

 

(131,428

)

 

 

(222,665

)

 

 

(234,882

)

Prepaid expenses and other current assets

 

6,054

 

 

 

10,443

 

 

 

5,963

 

 

 

7,943

 

Deferred contract costs

 

3,740

 

 

 

(1,549

)

 

 

438

 

 

 

(1,915

)

Accounts payable and accrued liabilities

 

19,569

 

 

 

14,093

 

 

 

(14,238

)

 

 

5,943

 

Accrued compensation and benefits

 

27,269

 

 

 

45,035

 

 

 

(73,431

)

 

 

(48,001

)

Deferred revenue

 

(10,759

)

 

 

(3,061

)

 

 

(21,602

)

 

 

(11,293

)

Income taxes

 

(73,428

)

 

 

(18,541

)

 

 

(74,463

)

 

 

(6,465

)

Operating lease right-of-use assets and liabilities

 

(1,074

)

 

 

(14

)

 

 

(1,473

)

 

 

(2,363

)

Other assets and liabilities

 

(710

)

 

 

(12,819

)

 

 

4,674

 

 

 

(7,578

)

Net cash provided by/(used in) operating activities

 

189,526

 

 

 

42,714

 

 

 

(54,876

)

 

 

(37,282

)

Cash flows from investing activities:

 

 

 

 

 

 

 

Purchases of property and equipment and capitalized software

 

(10,509

)

 

 

(17,206

)

 

 

(16,772

)

 

 

(40,198

)

Proceeds from divestitures

 

 

 

 

 

 

 

12,895

 

 

 

736

 

Other

 

 

 

 

(2,165

)

 

 

 

 

 

(2,165

)

Net cash used in investing activities

 

(10,509

)

 

 

(19,371

)

 

 

(3,877

)

 

 

(41,627

)

Cash flows from financing activities:

 

 

 

 

 

 

 

Cash dividends paid to Maximus shareholders

 

(17,821

)

 

 

(16,901

)

 

 

(34,159

)

 

 

(34,961

)

Purchases of Maximus common stock

 

(114,440

)

 

 

(77,850

)

 

 

(155,002

)

 

 

(306,443

)

Tax withholding related to RSU vesting

 

 

 

 

 

 

 

(17,325

)

 

 

(16,441

)

Payments for debt financing costs

 

 

 

 

(1,658

)

 

 

 

 

 

(1,658

)

Proceeds from borrowings

 

300,000

 

 

 

524,000

 

 

 

665,000

 

 

 

959,000

 

Principal payments for debt

 

(332,500

)

 

 

(418,375

)

 

 

(465,000

)

 

 

(597,639

)

Other, including customer escrowed funds

 

51,484

 

 

 

(282

)

 

 

50,109

 

 

 

(1,181

)

Net cash (used in)/provided by financing activities

 

(113,277

)

 

 

8,934

 

 

 

43,623

 

 

 

677

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(568

)

 

 

791

 

 

 

(632

)

 

 

(1,593

)

Net change in cash, cash equivalents, and restricted cash

 

65,172

 

 

 

33,068

 

 

 

(15,762

)

 

 

(79,825

)

Cash, cash equivalents, and restricted cash, beginning of period

 

179,525

 

 

 

122,870

 

 

 

260,459

 

 

 

235,763

 

Cash, cash equivalents, and restricted cash, end of period

$

244,697

 

 

$

155,938

 

 

$

244,697

 

 

$

155,938

 

Maximus, Inc.

Consolidated Results of Operations by Segment

(Unaudited)

 

 

For the Three Months Ended March 31, 2026

(dollars in thousands)

U.S. Federal Services

 

% (1 )

 

U.S. Services

 

% (1 )

 

Outside the U.S.

 

% (1 )

 

Total

Revenue

$

753,143

 

 

 

$

415,754

 

 

 

$

137,070

 

 

 

 

$

1,305,967

 

Cost of revenue

 

527,698

 

70.1

%

 

 

315,245

 

75.8

%

 

 

120,760

 

 

88.1

%

 

 

963,703

 

Gross profit

 

225,445

 

29.9

%

 

 

100,509

 

24.2

%

 

 

16,310

 

 

11.9

%

 

 

342,264

 

Other segment items (2)

 

92,741

 

12.3

%

 

 

61,919

 

14.9

%

 

 

19,395

 

 

14.1

%

 

 

174,055

 

Segment operating income/(loss)

$

132,704

 

17.6

%

 

$

38,590

 

9.3

%

 

$

(3,085

)

 

(2.3

)%

 

 

168,209

 

Other (4)

 

 

 

 

 

 

 

 

 

 

 

 

 

576

 

Amortization of intangible assets

 

 

 

 

 

 

 

 

 

 

 

 

 

(20,298

)

Operating income

 

 

 

 

 

 

 

 

 

 

 

 

$

148,487

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended March 31, 2025

(dollars in thousands)

U.S. Federal Services

 

% (1)

 

U.S. Services

 

% (1)

 

Outside the U.S.

 

% (1)

 

Total

Revenue

$

777,927

 

 

1

$

442,350

 

 

 

$

141,509

 

 

 

 

$

1,361,786

 

Cost of revenue

 

575,869

 

74.0

%

 

 

330,580

 

74.7

%

 

 

116,516

 

 

82.3

%

 

 

1,022,965

 

Gross profit

 

202,058

 

26.0

%

 

 

111,770

 

25.3

%

 

 

24,993

 

 

17.7

%

 

 

338,821

 

Other segment items (2)

 

83,076

 

10.7

%

 

 

57,963

 

13.1

%

 

 

20,197

 

 

14.3

%

 

 

161,236

 

Segment operating income

$

118,982

 

15.3

%

 

$

53,807

 

12.2

%

 

$

4,796

 

 

3.4

%

 

 

177,585

 

Divestiture-related gains/(charges) (3)

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,002

)

Other (4)

 

 

 

 

 

 

 

 

 

 

 

 

 

(619

)

Amortization of intangible assets

 

 

 

 

 

 

 

 

 

 

 

 

 

(22,996

)

Operating income

 

 

 

 

 

 

 

 

 

 

 

 

$

152,968

 

 

For the Six Months Ended March 31, 2026

(dollars in thousands)

U.S. Federal Services

 

% (1)

 

U.S. Services

 

% (1)

 

Outside the U.S.

 

% (1)

 

Total

Revenue

$

1,539,744

 

 

1

$

831,002

 

 

 

$

280,267

 

 

 

 

$

2,651,013

 

Cost of revenue

 

1,099,364

 

71.4

%

 

 

646,099

 

77.7

%

 

 

244,616

 

 

87.3

%

 

 

1,990,079

 

Gross profit

 

440,380

 

28.6

%

 

 

184,903

 

22.3

%

 

 

35,651

 

 

12.7

%

 

 

660,934

 

Other segment items (2)

 

177,943

 

11.6

%

 

 

117,027

 

14.1

%

 

 

40,116

 

 

14.3

%

 

 

335,086

 

Segment operating income

$

262,437

 

17.0

%

 

$

67,876

 

8.2

%

 

$

(4,465

)

 

(1.6

)%

 

 

325,848

 

Divestiture-related gains/(charges) (3)

 

 

 

 

 

 

 

 

 

 

 

 

 

8,985

 

Other (4)

 

 

 

 

 

 

 

 

 

 

 

 

 

462

 

Amortization of intangible assets

 

 

 

 

 

 

 

 

 

 

 

 

 

(40,598

)

Operating income

 

 

 

 

 

 

 

 

 

 

 

 

$

294,697

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Six Months Ended March 31, 2025

(dollars in thousands)

U.S. Federal Services

 

% (1)

 

U.S. Services

 

% (1)

 

Outside the U.S.

 

% (1)

 

Total

Revenue

$

1,558,582

 

 

 

$

894,600

 

 

 

$

311,279

 

 

 

 

$

2,764,461

 

Cost of revenue

 

1,183,209

 

75.9

%

 

 

687,826

 

76.9

%

 

 

253,048

 

 

81.3

%

 

 

2,124,083

 

Gross profit

 

375,373

 

24.1

%

 

 

206,774

 

23.1

%

 

 

58,231

 

 

18.7

%

 

 

640,378

 

Other segment items (2)

 

157,291

 

10.1

%

 

 

112,121

 

12.5

%

 

 

45,315

 

 

14.6

%

 

 

314,727

 

Segment operating income

$

218,082

 

14.0

%

 

$

94,653

 

10.6

%

 

$

12,916

 

 

4.1

%

 

 

325,651

 

Divestiture-related gains/(charges) (3)

 

 

 

 

 

 

 

 

 

 

 

 

 

(39,343

)

Other (4)

 

 

 

 

 

 

 

 

 

 

 

 

 

(522

)

Amortization of intangible assets

 

 

 

 

 

 

 

 

 

 

 

 

 

(46,031

)

Operating income

 

 

 

 

 

 

 

 

 

 

 

 

$

239,755

 

 

(1) Percentage of respective revenue, as applicable.

(2) Other segment items are principally selling, general, and administrative expenses allocated to segments.
(3) During fiscal years 2026 and 2025, we divested businesses from our U.S. Services and Outside the U.S. Segments, respectively.

(4) Other expenses include credits and costs that are not allocated to a particular segment.

Maximus, Inc.

Consolidated Free Cash Flows – Non-GAAP

(Unaudited)

 

For the Three Months Ended

 

For the Six Months Ended

 

March 31, 2026

 

March 31, 2025

 

March 31, 2026

 

March 31, 2025

 

(in thousands)

Net cash provided by/(used in) operating activities

 

189,526

 

 

 

42,714

 

 

 

(54,876

)

 

 

(37,282

)

Purchases of property and equipment and capitalized software

 

(10,509

)

 

 

(17,206

)

 

 

(16,772

)

 

 

(40,198

)

Free cash flow (Non-GAAP)

$

179,017

 

 

$

25,508

 

 

$

(71,648

)

 

$

(77,480

)

Maximus, Inc.

Non-GAAP Adjusted Results – Adjusted EBITDA, Adjusted Net Income, and Adjusted Diluted Earnings per Share

(Unaudited)

 

For the Three Months Ended

 

For the Six Months Ended

 

March 31, 2026

 

March 31, 2025

 

March 31, 2026

 

March 31, 2025

 

(dollars in thousands, except per share data)

Net income

$

98,063

 

 

$

96,569

 

 

$

192,006

 

 

$

137,765

 

Provision for income taxes

 

28,471

 

 

 

35,893

 

 

 

60,795

 

 

 

63,650

 

Interest expense

 

22,111

 

 

 

21,469

 

 

 

42,927

 

 

 

38,991

 

Other (income)/expense, net

 

(158

)

 

 

(963

)

 

 

(1,031

)

 

 

(651

)

Amortization of intangible assets

 

20,298

 

 

 

22,996

 

 

 

40,598

 

 

 

46,031

 

Divestiture-related charges/(gains)

 

 

 

 

1,002

 

 

 

(8,985

)

 

 

39,343

 

Depreciation and amortization of property, equipment, and capitalized software

 

12,328

 

 

 

9,440

 

 

 

25,217

 

 

 

17,895

 

Capitalized software impairment charges

 

6,914

 

 

 

 

 

 

6,914

 

 

 

 

Adjusted EBITDA (Non-GAAP)

$

188,027

 

 

$

186,406

 

 

$

358,441

 

 

$

343,024

 

 

 

 

 

 

 

 

 

Net income margin (GAAP)*

 

7.5

%

 

 

7.1

%

 

 

7.2

%

 

 

5.0

%

Adjusted EBITDA margin (Non-GAAP)*

 

14.4

%

 

 

13.7

%

 

 

13.5

%

 

 

12.4

%

 

 

 

 

 

 

 

 

* Margins are calculated as a percentage of revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

$

98,063

 

 

$

96,569

 

 

$

192,006

 

 

$

137,765

 

Add back: Amortization of intangible assets, net of tax

 

14,960

 

 

 

16,948

 

 

 

29,921

 

 

 

33,925

 

Add back: Divestiture-related charges/(gains), net of tax

 

 

 

 

1,002

 

 

 

(6,622

)

 

 

39,343

 

Adjusted net income excluding amortization of intangible

assets and divestiture-related adjustments (Non-GAAP)

$

113,023

 

 

$

114,519

 

 

$

215,305

 

 

$

211,033

 

 

 

 

 

 

 

 

 

Diluted earnings per share

$

1.80

 

 

$

1.69

 

 

$

3.50

 

 

$

2.35

 

Add back: Effect of amortization of intangible assets on diluted

earnings per share

 

0.27

 

 

 

0.30

 

 

 

0.54

 

 

 

0.58

 

Add back: Effect of divestiture-related charges/(gains) on

diluted earnings per share

 

 

 

 

0.02

 

 

 

(0.12

)

 

 

0.67

 

Adjusted diluted earnings per share excluding amortization of

intangible assets and divestiture-related adjustments (Non-GAAP)

$

2.07

 

 

$

2.01

 

 

$

3.92

 

 

$

3.60

 

 

James Francis, VP – IR

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Software Defense Consulting Artificial Intelligence Data Management Professional Services Technology Government Technology

MEDIA:

Logo
Logo

InfuSystem Announces Financial Results for First Quarter 2026

InfuSystem Announces Financial Results for First Quarter 2026

Net Revenues of $33.7 million Representing a 3% Reduction from the Prior Year

Net income of $1.0 million

Adjusted EBITDA (non-GAAP) of $6.4 million

Adjusted EBITDA (non-GAAP) margin expanded by 1% to 19%

Reaffirms Full-Year 2026 Guidance

ROCHESTER HILLS, Mich.–(BUSINESS WIRE)–InfuSystem Holdings, Inc. (NYSE American:INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today reported financial results for the first quarter ended March 31, 2026.

2026 First Quarter Overview:

  • Net revenues totaled $33.7 million, a decrease of 3% vs. prior year.

    • Patient Services net revenue was $22.1 million, an increase of 6% vs. prior year.

    • Device Solutions net revenue was $11.6 million, a decrease of 17% vs. prior year.

  • Gross profit was $19.7 million, an increase of 3% vs. prior year.

  • Gross margin was 58%, an increase of 3% vs. prior year.

  • Net income was $1.0 million, or $0.05 per diluted share vs. prior year net loss of $0.3 million, or $0.01 per diluted share.

  • Adjusted earnings before interest, income taxes, depreciation, and amortization (“Adjusted EBITDA”) (non-GAAP) was $6.4 million, even with the prior year.

  • Adjusted EBITDA margin was 18.9% an increase of 0.7% vs. prior year.

  • Stock Repurchases totaled $856 thousand for the quarter.

  • Company liquidity totaled $57.1 million, as of March 31, 2026.

Management Discussion

Carrie Lachance, Chief Executive Officer of InfuSystem commented, “Overall, we delivered a solid quarter that reflects both disciplined execution and meaningful strategic progress. While GAAP revenue declined modestly year over year to $33.7 million, that decline was expected and resulted from the strategic decision to restructure our GE Healthcare biomedical services contract. On a pro‑forma basis, net revenue grew 1.7%, and just as importantly, profitability held strong. We delivered $6.4 million of Adjusted EBITDA, essentially flat year over year, due to margins improving to 18.9%. As previously discussed, reducing revenue to improve our overall profitability was a deliberate and, we believe, value‑accretive decision. The restructuring reduced first‑quarter revenue by $1.6 million, but it enabled a significantly larger reduction in direct contract expenses. While GAAP revenue is lower, the economics of the business are better, and that’s clearly showing up in our Adjusted EBITDA performance.”

“Wound care continues to be an exciting growth engine for InfuSystem. First‑quarter net revenue reached $2.1 million, more than doubling year-over-year. While currently just 6% of total revenue, we believe the growth rate indicative of the new therapy’s potential. Roughly 60% of the year-over-year growth came from compression devices, which we began rolling out last year and expanded further this quarter. We initially introduced Pneumatic Compression Devices, which are highly effective at treating even the most high risk, chronic patient conditions. This quarter, we added Adjustable Compression Wraps, which are less complex and suitable for a much broader group of lymphedema patients. This significantly expands our addressable market and positions us well for sustained growth in the wound care category.”

“On March 1, 2026, after nearly two years of intense preparation, we successfully went live on our new ERP system. I would call this transformational. While implementations of this scale always come with early‑stage adjustments, the hardest part is behind us. This system completely changes how we operate. Our data is now integrated, workflows are connected, and processes are standardized across the business. The benefits span the entire organization. We expect improved productivity, better cost and margin visibility, stronger pricing insights, more efficient utilization of our medical device fleet, and improved working capital management. Just as important, the ERP gives us a scalable platform to support future growth. We’re already identifying enhancements that offer fast payback and high returns,” concluded Ms. Lachance.

2026 First Quarter Financial Review

Net revenues for the quarter ended March 31, 2026 (“2026 First Quarter”) were $33.7 million, a decrease of $1.0 million, or 3%, compared to $34.7 million for the quarter ended March 31, 2025 (“2025 First Quarter”). As we announced during our review of the 2025 third quarter, we restructured our largest biomedical services contract and, consequently, we started 2026 at a reduced revenue volume of $1.6 million, or 4.6%, for the 2026 First Quarter and $7.1 million, or 5.5% for the full year. This was a necessary change that has had an immediate favorable impact on our reported earnings and cash flows since we also achieved an even larger reduction in our expenses. After adjusting for this decrease, our pro-forma growth rate was 1.7% during the 2026 First Quarter as compared with the prior year period.

Patient Services net revenue of $22.1 million increased $1.3 million, or 6%, during the 2026 First Quarter compared to the 2025 First Quarter. This increase was primarily attributable to additional treatment volume in Oncology and Wound Care which were partially offset by a lower amount in Pain Management. The improved volume and collections benefited Oncology revenue by $0.4 million or 2.4%, and Wound Care treatment revenue by $1.1 million, or 116.0%. Pain Management revenue decreased by $0.2 million, or 15.1%. The Wound Care net revenues included sales of compression therapy devices stemming from two new supplier relationships which were added after the end of the three-month period of 2025. Sales for the first of these new supplier relationships, which include Pneumatic Compression Devices (PCD’s), started during the third quarter of 2025 and the second supplier relationship, which is a manufacturer of Adjustable Compression Wraps (ACW’s), began during the current period. On a combined basis, compression therapy devices represented over 60% of the growth in Wound Care.

Device Solutions net revenue of $11.6 million decreased $2.4 million, or 17%, during the 2026 First Quarter compared to the 2025 First Quarter. This decrease included a reduction in biomedical services revenue of $1.3 million, equipment rentals of $0.4 million and equipment sales of $1.0 million. These decreases were partially offset by an increase in disposable medical supplies of $0.3 million. A portion of the decrease in biomedical services revenue totaling $1.6 million reflected a reduction in the volume and service level of devices on contract with GE Healthcare which, as mentioned above, was restructured during the third quarter of 2025. These decreases were partially offset by additional volume with other customers. The decrease in rental revenue and the decreased equipment sales are both related to a large customer rental buyout that began in the 2025 First Quarter. The buyout elevated the amount of equipment sales in the prior year and reduced quarterly rental revenues during the subsequent quarters including the current quarter.

Gross profit of $19.7 million for the 2026 First Quarter increased $0.5 million, or 3%, from $19.2 million for the 2025 First Quarter. This increase was due to the increase in gross margin partially offset by the lower net revenues. Gross margin increased to 58.4% during the three-month period of 2026 compared to 55.2% during the same prior year period. Gross profit was higher in the Patient Services segment and lower in the Devices Solutions segments. Gross margin was higher for both segments.

Patient Services gross profit was $14.3 million during the 2026 First Quarter, representing an increase of $1.1 million, or 9%, compared to the 2025 First Quarter. The improvement reflected increased net revenue and a higher gross margin, which increased from the prior year by 1.3% to 64.8%. The increase in gross margin reflected lower pump disposal and maintenance expenses offset partially by unfavorable product mix favoring lower gross margin revenue categories. Pump disposal expenses include retirements of damaged pumps and reserves for missing pumps. Pump maintenance expenses include annual preventative maintenance certification and repairs and are performed by the Device Solutions segment. On a combined basis pump disposal and maintenance expenses decreased by $0.3 million during the 2026 First Quarter compared to the prior year period. The unfavorable gross margin mix was mainly related to the increase in revenue related to wound care treatments, which have lower average gross margin than other Patient Services revenue categories.

Device Solutions gross profit during the 2026 First Quarter was $5.4 million, representing an decrease of $0.6 million, or 10%, compared to the 2025 First Quarter. The decrease was due to the reduction in net revenue offset partially by an increase in gross margin. The Device Solutions gross margin was 46.3% during the current period, which was 3.4% higher than the same prior year period. This increase in gross margin was primarily due to the aforementioned restructuring of the biomedical services contract with GE Healthcare which resulted in reduced expenses greater than the related reduction in net revenue. Reduced contract expenses included a reduction in biomedical personnel, a reduced amount of medical device replacement parts and lower travel expenses. These impacts improved the gross margin for the device solutions segment by 7.2%. Additional gross margin improvements totaling 0.6% were achieved though ongoing initiatives focused on improved procurement costs of materials and increased biomedical productivity. These benefits in gross margin were partially offset by cost inflation impacts from increased employee wage rates and higher healthcare expenses, which on a combined basis, reduced the Device Solutions segment gross margin by 2.5%, and unfavorable product mix impacts disfavoring higher gross margin revenues, such as rental revenue and sales of used equipment, which reduced gross margin by 1.9%. Higher wages were the result of typical annual merit and cost of living increases, however, the increase in the cost of health care benefits were significantly higher than amounts experience in prior years.

Selling and marketing expenses for the 2026 First Quarter were $3.1 million, representing an increase of $0.1 million, or 3%, compared to selling and marketing expenses for the 2025 First Quarter. Selling and marketing expenses as a percentage of net revenues was 9.1% representing a increase from the prior year period amount of 8.6%. This increase reflected an increase in sales team headcount, increased travel expenses and inflationary impacts including an increase in employee healthcare expenses. These amounts were partially offset by a reduction in commission expenses.

General and administrative (“G&A”) expenses for the 2026 First Quarter were $14.8 million, a decrease of $0.5 million, or 3%, from the 2025 First Quarter. The amount for the three-month period of 2025 included a one-time accrued severance expense of $1.0 million for the Company’s outgoing CEO. Additional reductions included a $0.3 million reduction in the accrual for management bonuses, lower accounting fees totaling $0.2 million and $0.1 million in reduced travel expenses. These decreases were partially offset by increases in other expenses including; $0.4 million in increased expenses related to information technology and business applications upgrades including the replacement of the Company’s enterprise resource planning system (ERP), additional personnel directly related to the increased Patient Services net revenue including revenue cycle personnel totaling $0.3 million, a $0.1 million increase in stock-based compensation expenses and cost inflation impacts from increased employee wage rates and higher healthcare expenses totaling $0.4 million. The ERP system upgrade project expenses were higher during the current period due to a higher intensity of activities related to the go-live phase of the project which occurred on March 1, 2026. While additional costs are expected to be incurred during the post go-live phase to support system stabilization and enhancement activities, project expenses are expected to begin to taper down during future quarterly periods. Higher wages were the result of typical annual merit and cost of living increases, however, the increase in the cost of health care benefits were significantly higher than amounts experience in prior years. General and Administrative expenses as a percentage of net revenues for the three-month period of 2026 decreased to 43.9% compared to 44.1% for the same prior year period.

Net income for the 2026 First Quarter was $1.0 million, or $0.05 per diluted share, compared to a net loss of $0.3 million, or $0.01 per diluted share for the 2025 First Quarter.

Adjusted EBITDA, a non-GAAP measure, for the 2026 First Quarter was $6.4 million, or 18.9% of net revenue, and increased by $32 thousand compared to Adjusted EBITDA for the 2025 First Quarter of $6.3 million, or 18.2% of prior period net revenue.

Balance sheet, cash flows and liquidity

During the three-month period ended March 31, 2026, operating cash flow provided cash totaling $1.0 million compared with $1.8 million during the same period in 2025. The decrease reflected a higher increase in working capital during 2026. Capital expenditures, which include purchases of medical devices, totaled $1.8 million during the three-month period of 2026 which was $1.6 million, or 46%, lower than the amount purchased during the same prior year period reflecting revenue growth in business lines that are less capital intensive such as wound care and sales of disposable medical supplies. Also during the three-month period ended March 31, 2026, the Company repurchased $0.8 million of its Common Stock.

As of March 31, 2026, available liquidity totaled $57.1 million and consisted of $55.0 million in available borrowing capacity under the Company’s revolving line of credit plus cash and cash equivalents of $2.1 million. Net debt, a non-GAAP measure (calculated as total debt of $19.6 million less cash and cash equivalents of $2.1 million) as of March 31, 2026 was $17.5 million representing an increase of $1.1 million as compared to net debt of $16.4 million as of December 31, 2025 (calculated as total debt of $19.6 million less cash and cash equivalents of $3.2 million). Our ratio of Adjusted EBITDA to net debt (non-GAAP) for the last four quarters was 0.56 to 1.00 (calculated as net debt of $17.5 million divided by Adjusted EBITDA of $31.5 million).

Full Year 2026 Guidance

InfuSystem is reaffirming annual net revenue guidance for the full year 2026. After adjusting for the impact of the reduced revenue related to the GE Healthcare contract restructuring, pro-forma net revenue growth is estimated to be between 6% to 8% for 2026. We also are continuing to forecast Adjusted EBITDA margin (non-GAAP) to be in the mid to low 20%’s. This includes the implementation expenses for the Company’s upgraded information technology systems which went on-line on March 1, 2026. The Company intends to continue to update its annual guidance throughout the year.

The full year 2026 guidance reflects management’s current expectations for operational performance, given the current market conditions. This includes our best estimate of revenue and Adjusted EBITDA. The Company and its businesses are subject to certain risks, including those risk factors discussed in our most recent Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 27, 2026. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

Conference Call

The Company will conduct a conference call for all interested investors on Thursday, May 7, 2026, at 9:00 a.m. Eastern Time to discuss its first quarter 2026 financial results. The call will include discussion of Company developments, forward-looking statements and other material information about business and financial matters.

To participate in this call, please dial (833) 366-1127 or (412) 902-6773, or listen via a live webcast, which is available in the Investors section of the Company’s website at https://ir.infusystem.com/. A replay of the call will be available by visiting https://ir.infusystem.com/ or by calling (855) 669-9658 or (412) 317-0088, replay access code 1097864, through August 7, 2026.

Non-GAAP Measures

This press release contains information prepared in conformity with GAAP as well as non-GAAP financial information. Non-GAAP financial measures presented in this press release include EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, net debt and Adjusted EBITDA to net debt ratio. The Company believes that the non-GAAP financial measures presented in this press release provide useful information to the Company’s management, investors and other interested parties about the Company’s operating performance because they allow them to understand and compare the Company’s operating results during the current periods to the prior year periods in a more consistent manner. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP, and similarly titled non-GAAP measures may be calculated differently by other companies. The Company calculates those non-GAAP measures by adjusting for non-recurring or non-core items that are not part of the normal course of business. A reconciliation of those measures to the most directly comparable GAAP measures is provided in the accompanying schedule, titled “GAAP to Non-GAAP Reconciliation” below. Future period non-GAAP guidance includes adjustments for items not indicative of our core operations, which may include, without limitation, items included in the accompanying schedule below. Such adjustments may be affected by changes in ongoing assumptions and judgments, as well as non-core, nonrecurring, unusual or unanticipated changes, expenses or gains or other items that may not directly correlate to the underlying performance of our business operations. The exact amounts of these adjustments are not currently determinable but may be significant. It is therefore not practicable to provide the comparable GAAP measures or reconcile this non-GAAP guidance to the most comparable GAAP measures and, therefore, such comparable GAAP measures and reconciliations are excluded from this release in reliance upon applicable SEC staff guidance.

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc. (NYSE American:INFU), is a leading national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-platform model. The first platform is Patient Services, providing last-mile solutions for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient Services segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second platform, Device Solutions, supports the Patient Services platform and leverages strong service orientation to win incremental business from its direct payer clients. The Device Solutions segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada.

Forward-Looking Statements

The financial results in this press release reflect preliminary results, which are not final until the Companys quarterly report on Form 10-Q for the quarter ended March 31, 2026 is filed. In addition, certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements relating to future actions, our share repurchase program and capital allocation strategy, business plans, strategic partnerships, growth initiatives, objectives and prospects, future operating or financial performance, guidance and expected new business relationships and the terms thereof (including estimated potential revenue under new or existing contracts). The words believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “goal,” “expect,” “strategy,” “future,” “likely,variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to factors, risks and uncertainties that could cause actual results to differ materially, including, but not limited to, our ability to successfully execute on our growth initiatives and strategic partnerships, our ability to enter into definitive agreements for the new business relationships on expected terms or at all, our ability to generate estimated potential revenue amounts under new or existing contracts, the uncertain impact of disruptions caused by public health emergencies or extreme weather or other climate change-related events, our dependence on estimates of collectible revenue, potential litigation, changes in third-party reimbursement processes, changes in law, global financial conditions and recessionary risks, rising inflation and interest rates, supply chain disruptions, systemic pressures in the banking sector, including disruptions to credit markets, the Company’s ability to remediate any material weaknesses in internal control over financial reporting, contributions from acquired businesses or new business lines, products or services and other risk factors disclosed in the Companys most recent Annual Report on Form 10-K and, to the extent applicable, quarterly reports on Form 10-Q. Our strategic partnerships are subject to similar factors, risks and uncertainties. All forward-looking statements made in this press release speak only as of the date hereof. We do not undertake any obligation to update any forward-looking statements to reflect future events or circumstances, except as required by law.

Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.

FINANCIAL TABLES FOLLOW

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

Three Months Ended

March 31,

(in thousands, except share and per share data)

 

2026

 

 

 

2025

 

 

 

 

 

Net revenues

$

33,684

 

 

$

34,716

 

Cost of revenues

 

14,002

 

 

 

15,549

 

Gross profit

 

19,682

 

 

 

19,167

 

 

 

 

 

Selling, general and administrative expenses:

 

 

 

Amortization of intangibles

 

209

 

 

 

248

 

Selling and marketing

 

3,080

 

 

 

2,985

 

General and administrative

 

14,803

 

 

 

15,316

 

 

 

 

 

Total selling, general and administrative

 

18,092

 

 

 

18,549

 

 

 

 

 

Operating income

 

1,590

 

 

 

618

 

Other expense:

 

 

 

Interest expense

 

(255

)

 

 

(336

)

Other income (expense)

 

82

 

 

 

(29

)

 

 

 

 

Income before income taxes

 

1,417

 

 

 

253

 

Provision for income taxes

 

(400

)

 

 

(520

)

Net income (loss)

$

1,017

 

 

$

(267

)

Net income (loss) per share:

 

 

 

Basic

$

0.05

 

 

$

(0.01

)

Diluted

$

0.05

 

 

$

(0.01

)

Weighted average shares outstanding:

 

 

 

Basic

 

20,211,045

 

 

 

21,125,019

 

Diluted

 

20,893,767

 

 

 

21,125,019

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

SEGMENT REPORTING

(UNAUDITED)

 

 

Three Months Ended

March 31,

 

Better/

(Worse)

(in thousands)

 

 

2026

 

 

 

2025

 

 

 

 

 

 

 

 

 

Net revenues:

 

 

 

 

 

 

Patient Services

 

$

22,105

 

 

$

20,774

 

 

$

1,331

 

Device Solutions

 

 

13,221

 

 

 

15,824

 

 

 

(2,603

)

Less: elimination of inter-segment revenues (a)

 

 

(1,642

)

 

 

(1,882

)

 

 

240

 

Total Device Solutions

 

 

11,579

 

 

 

13,942

 

 

 

(2,363

)

Total

 

 

33,684

 

 

 

34,716

 

 

 

(1,032

)

Gross profit:

 

 

 

 

 

 

Patient Services

 

 

14,323

 

 

 

13,185

 

 

 

1,138

 

Device Solutions

 

 

5,359

 

 

 

5,982

 

 

 

(623

)

Total

 

$

19,682

 

 

$

19,167

 

 

$

515

 

(a)

 

Inter-segment allocations are for cleaning and repair services performed on medical equipment.

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(UNAUDITED)

NET INCOME TO EBITDA, ADJUSTED EBITDA, NET INCOME MARGIN, ADJUSTED EBITDA MARGIN AND NET REVENUE GROWTH RATE TO PRO FORMA REVENUE GROWTH RATE:

 

 

Three Months Ended

March 31,

(in thousands)

 

 

2026

 

 

 

2025

 

 

 

 

 

 

GAAP net income (loss)

 

$

1,017

 

 

$

(267

)

Adjustments:

 

 

 

 

Interest expense

 

 

255

 

 

 

336

 

Income tax provision

 

 

400

 

 

 

520

 

Depreciation

 

 

3,045

 

 

 

3,072

 

Amortization

 

 

209

 

 

 

248

 

 

 

 

 

 

Non-GAAP EBITDA

 

$

4,926

 

 

$

3,909

 

 

 

 

 

 

Stock compensation costs

 

 

1,233

 

 

 

1,108

 

Medical equipment reserve and disposals (1)

 

 

187

 

 

 

222

 

Management reorganization/transition costs (2)

 

 

 

 

 

1,028

 

Certain other non-recurring costs

 

 

9

 

 

 

56

 

 

 

 

 

 

Non-GAAP Adjusted EBITDA

 

$

6,355

 

 

$

6,323

 

 

 

 

 

 

GAAP Net Revenues

 

$

33,684

 

 

$

34,716

 

Net Revenue Growth from Prior Year

 

 

(3.0

)%

 

 

Pro-Forma Net Revenue Adjustment (3)

 

$

 

 

$

(1,605

)

Non-GAAP Pro-Forma Net Revenue

 

$

33,684

 

 

$

33,111

 

Non-GAAP Pro-Forma Net Revenue Growth from Prior Year

 

 

1.7

%

 

 

Net Income Margin (4)

 

 

3.0

%

 

 

(0.8

)%

Non-GAAP Adjusted EBITDA Margin (5)

 

 

18.9

%

 

 

18.2

%

Business Application (“ERP”) Upgrade Investment (6)

 

$

883

 

 

$

466

 

(1)

 

Amounts represent a non-cash (benefit) expense recorded to adjust the reserve for missing medical equipment and is being added back due to its similarity to depreciation.

(2)

 

Includes severance compensation for the outgoing CEO totaling $1.0 million.

(3)

 

Amount represents effect on net revenue related to a restructuring of a Biomedical Services Contract which took effect on January 1, 2026. Net revenue adjustment amount for 2025 presents the impact as though the change in the contract had occurred on January 1, 2025.

(4)

 

Net Income Margin is defined as GAAP Net Income as a percentage of GAAP Net Revenues.

(5)

 

Non-GAAP Adjusted EBITDA Margin is defined as Non-GAAP Adjusted EBITDA as a percentage of GAAP Net Revenues.

(6)

 

Represents expenses associated with a project to upgrade the Company’s information technology and business applications including a replacement of our main enterprise resource planning (“ERP”) application. The project was launched during the second quarter of 2024 and was completed during the first quarter of 2026. Amounts are included in GAAP net income and have not been added back in the measurement of Non-GAAP Adjusted EBITDA.

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

 

As of

(in thousands, except par value and share data)

 

March 31,

2026

 

December 31,

2025

 

 

 

 

 

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

2,106

 

 

$

3,186

 

Accounts receivable, net

 

 

23,980

 

 

 

22,901

 

Inventories, net

 

 

5,832

 

 

 

5,391

 

Other current assets

 

 

4,744

 

 

 

4,858

 

 

 

 

 

 

Total current assets

 

 

36,662

 

 

 

36,336

 

Medical equipment for sale or rental

 

 

3,669

 

 

 

4,589

 

Medical equipment in rental service, net of accumulated depreciation

 

 

34,255

 

 

 

34,456

 

Property & equipment, net of accumulated depreciation

 

 

3,217

 

 

 

3,359

 

Goodwill

 

 

3,710

 

 

 

3,710

 

Intangible assets, net

 

 

6,656

 

 

 

6,866

 

Operating lease right of use assets

 

 

3,844

 

 

 

4,178

 

Deferred income taxes

 

 

4,232

 

 

 

4,640

 

Derivative financial instruments

 

 

766

 

 

 

748

 

Other assets

 

 

1,646

 

 

 

1,678

 

 

 

 

 

 

Total assets

 

$

98,657

 

 

$

100,560

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

9,632

 

 

$

10,821

 

Other current liabilities

 

 

7,510

 

 

 

9,361

 

 

 

 

 

 

Total current liabilities

 

 

17,142

 

 

 

20,182

 

Long-term debt

 

 

19,646

 

 

 

19,625

 

Operating lease liabilities, net of current portion

 

 

3,120

 

 

 

3,427

 

 

 

 

 

 

Total liabilities

 

 

39,908

 

 

 

43,234

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

Preferred stock, $0.0001 par value: authorized 1,000,000 shares; none issued

 

 

 

 

 

 

Common stock, $0.0001 par value: authorized 200,000,000 shares; 20,178,890 issued and outstanding as of March 31, 2026 and 20,209,636 issued and outstanding as of December 31, 2025

 

 

2

 

 

 

2

 

Additional paid-in capital

 

 

118,713

 

 

 

117,461

 

Accumulated other comprehensive income

 

 

575

 

 

 

565

 

Retained deficit

 

 

(60,541

)

 

 

(60,702

)

 

 

 

 

 

Total stockholders’ equity

 

 

58,749

 

 

 

57,326

 

 

 

 

 

 

Total liabilities and stockholders’ equity

 

$

98,657

 

 

$

100,560

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

Three Months Ended March

31,

(in thousands)

 

 

2026

 

 

 

2025

 

 

 

 

 

 

OPERATING ACTIVITIES

 

 

 

 

Net income (loss)

 

$

1,017

 

 

$

(267

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

Provision for doubtful accounts

 

 

69

 

 

 

45

 

Depreciation

 

 

3,044

 

 

 

3,072

 

Loss on disposal of and reserve adjustments for medical equipment

 

 

202

 

 

 

257

 

Loss (gain) on sale of medical equipment

 

 

123

 

 

 

(838

)

Amortization of intangible assets

 

 

209

 

 

 

248

 

Amortization of deferred debt issuance costs

 

 

21

 

 

 

19

 

Stock-based compensation

 

 

1,233

 

 

 

1,108

 

Deferred income taxes

 

 

400

 

 

 

520

 

Changes in assets – (increase)/decrease:

 

 

 

 

Accounts receivable

 

 

(2,250

)

 

 

(2,095

)

Inventories

 

 

(203

)

 

 

433

 

Other current assets

 

 

(130

)

 

 

126

 

Other assets

 

 

563

 

 

 

729

 

Changes in liabilities – (decrease)/increase:

 

 

 

 

Accounts payable and other liabilities

 

 

(3,328

)

 

 

(1,577

)

NET CASH PROVIDED BY OPERATING ACTIVITIES

 

 

970

 

 

 

1,780

 

 

 

 

 

 

INVESTING ACTIVITIES

 

 

 

 

Purchase of medical equipment

 

 

(1,680

)

 

 

(3,284

)

Purchase of property and equipment

 

 

(157

)

 

 

(131

)

Proceeds from sale of medical equipment, property and equipment

 

 

577

 

 

 

754

 

NET CASH USED IN INVESTING ACTIVITIES

 

 

(1,260

)

 

 

(2,661

)

 

 

 

 

 

FINANCING ACTIVITIES

 

 

 

 

Principal payments on long-term debt

 

 

(6,145

)

 

 

(14,407

)

Cash proceeds from long-term debt

 

 

6,145

 

 

 

19,231

 

Common stock repurchased as part of share repurchase program

 

 

(809

)

 

 

(2,895

)

Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans

 

 

(165

)

 

 

(228

)

Cash proceeds from exercise of options and ESPP

 

 

184

 

 

 

159

 

NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

 

 

(790

)

 

 

1,860

 

 

 

 

 

 

Net change in cash and cash equivalents

 

 

(1,080

)

 

 

979

 

Cash and cash equivalents, beginning of period

 

 

3,186

 

 

 

527

 

Cash and cash equivalents, end of period

 

$

2,106

 

 

$

1,506

 

 

Barry Steele

Chief Financial Officer

(248) 260-2211

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: Health Hospitals Practice Management Other Health Managed Care General Health

MEDIA:

Logo
Logo

Spectrum Brands Holdings Reports Fiscal 2026 Second Quarter Results

Spectrum Brands Holdings Reports Fiscal 2026 Second Quarter Results

  • Second Quarter Net Sales Increased 4.9% and Organic Net Sales Excluding Foreign Exchange Increased 1.5%
  • Second Quarter Net Income From Continuing Operations of $22.5 Million and Adjusted EBITDA of $84.0 Million Increased by $20.7 Million and $12.7 Million, Respectively
  • Ended Second Quarter with Net Debt Leverage of 1.66x Adjusted EBITDA
  • Executed a Strategic Partnership in the Home and Personal Care Segment, Designed to Accelerate Long Term Growth of the Business
  • Updating Fiscal 2026 Framework, Continue to Expect Net Sales to be Flat to Up Low Single Digits and Approximately 50% Conversion of Adjusted EBITDA to Adjusted Free Cash Flow; Adjusted EBITDA is Now Expected to be Up Low to Mid Single Digits

MIDDLETON, Wis.–(BUSINESS WIRE)–
Spectrum Brands Holdings, Inc. (NYSE: SPB; “Spectrum Brands” or the “Company”), a leading global branded consumer products and home essentials company focused on driving innovation and providing exceptional customer service, today reported results from continuing operations for the second quarter of fiscal 2026 ended March 29, 2026.

“We are pleased with our results this quarter, where we returned to top-line growth for the first time since first quarter of fiscal 2025. Our key brands across Global Pet Care and Home & Garden continue to outperform the market driven by strong innovation and distribution gains. In Home & Personal Care, while net sales declined, adjusted EBITDA increased, demonstrating the positive impact of the actions taken over the past year. These results continue to reinforce the effectiveness of our strategic initiatives and the strength of our team. Looking forward, while we remain focused on the dynamic macroeconomic environment, our first half results represent meaningful progress for the full fiscal year. We are updating our earnings framework and increasing our Adjusted EBITDA expectation to low to mid single digit growth while maintaining our net sales expectation of flat to low single digit growth in fiscal 26,” said David Maura, Chairman and Chief Executive Officer of Spectrum Brands.

Mr. Maura continued, “On the strategic front, following quarter close, we entered into a partnership with Oaktree Capital Management on our Home & Personal Care business. The transaction includes a strategic $127 million cash investment from Oaktree Capital in the form of preferred equity and debt, and we will continue to own approximately 73% of the Appliances business. Upon closing, which is expected to occur later this month, the HPC subsidiaries will be designated as unrestricted subsidiaries with their own capital structure that is non-recourse to Spectrum Brands Holdings. We believe that a partnership with Oaktree Capital, who has a strong track record in disciplined capital allocation, validates our vision for creating value in our Appliances business through both organic and inorganic growth initiatives. Importantly, this transaction represents a meaningful step in our previously announced strategy of separating the HPC business from our Pet and Home & Garden businesses.”

Fiscal 2026 SecondQuarter Highlights

 

Three Month Periods Ended

 

 

 

 

(in millions, except per share and %)

 

March 29, 2026

 

March 30, 2025

 

Variance

Net sales

 

$

708.9

 

 

$

675.7

 

 

$

33.2

 

4.9

%

Gross profit

 

 

270.3

 

 

 

253.4

 

 

 

16.9

 

6.7

%

Gross profit margin

 

 

38.1

%

 

 

37.5

%

 

 

60

bps

Operating income

 

 

43.5

 

 

 

19.5

 

 

 

24.0

 

123.1

%

Net income from continuing operations

 

 

22.5

 

 

 

1.8

 

 

 

20.7

 

n/m

 

Net income from continuing operations margin

 

 

3.2

%

 

 

0.3

%

 

 

290

bps

Diluted earnings per share from continuing operations

 

$

0.96

 

 

$

0.06

 

 

$

0.90

 

n/m

 

Non-GAAP Operating Metrics

 

 

 

 

 

 

 

 

Adjusted EBITDA from continuing operations

 

$

84.0

 

 

$

71.3

 

 

 

12.7

 

17.8

%

Adjusted EBITDA margin

 

 

11.8

%

 

 

10.6

%

 

 

120

bps

Adjusted EPS from continuing operations

 

$

1.25

 

 

$

0.68

 

 

$

0.57

 

83.8

%

  • Net sales increased 4.9% with an increase in organic net sales of 1.5%, which excludes the impact of $22.9 million of favorable foreign exchange rates. The net sales increase was primarily due to strong performance in Global Pet Care and Home and Garden with market share gains across key brands. External factors including favorable weather and strategic order accelerations by certain retailers also contributed. This was partially offset by consumer demand softness in Home and Personal Care across both North America and Europe.

  • Gross profit and margin increased driven by pricing, cost improvement actions, and favorable foreign exchange partially offset by higher trade spend and higher tariff cost.

  • Operating income increased due to the increase in gross profit and lower operating expenses.

  • Net income from continuing operations and diluted earnings per share increased driven by higher operating income. Diluted earnings per share also benefited from a lower share count.

  • Adjusted EBITDA increased 17.8% and adjusted EBITDA margin increased 120 basis points driven by improved gross margins.

  • Adjusted diluted EPS increased to $1.25 due to higher adjusted EBITDA and a reduction to shares outstanding.

Fiscal 2026 Second Quarter Segment Level Data

Global Pet Care (GPC)

 

Three Month Periods Ended

 

 

 

 

(in millions, except %)

 

March 29, 2026

 

March 30, 2025

 

Variance

Net sales

 

$

299.3

 

 

$

269.2

 

 

$

30.1

 

11.2

%

Adjusted EBITDA

 

 

56.8

 

 

 

50.0

 

 

 

6.8

 

13.6

%

Adjusted EBITDA margin

 

 

19.0

%

 

 

18.6

%

 

 

40

bps

Net sales increased 11.2%. Excluding favorable foreign currency impacts, organic net sales increased 7.6%. Reported net sales in Companion Animal increased low double digits while sales in Aquatics increased mid single digits. North American net sales increased primarily driven by market share gains across Companion Animal brands and E-commerce channel strength. Organic net sales in EMEA increased across both categories due to continued brand strength and expanded distribution as well as a strategic acceleration of orders by certain retailers in advance of the SAP S4/HANA ERP implementation.

Adjusted EBITDA of $56.8 million increased from $50.0 million in the prior year, and adjusted EBITDA margins were 19.0% compared to 18.6% in the prior year. The increase in adjusted EBITDA and margin is due to higher sales volume, pricing and cost improvement actions partially offset by higher tariff cost and additional trade and investment spend.

Home & Garden (H&G)

 

Three Month Periods Ended

 

 

 

 

(in millions, except %)

 

March 29, 2026

 

March 30, 2025

 

Variance

Net sales

 

$

169.5

 

 

$

152.3

 

 

$

17.2

 

11.3

%

Adjusted EBITDA

 

 

34.8

 

 

 

26.7

 

 

 

8.1

 

30.3

%

Adjusted EBITDA margin

 

 

20.5

%

 

 

17.5

%

 

 

300

bps

Net sales increased 11.3% and organic net sales increased 11.2% due to favorable weather conditions positively impacting POS and retailer order patterns, with above-market growth across key brands.

Adjusted EBITDA of $34.8 million increased from $26.7 million in the prior year and adjusted EBITDA margins of 20.5% increased from 17.5% in the prior year primarily due to higher sales volume, productivity improvements and operational efficiencies partially offset by higher trade spend and unfavorable mix.

Home & Personal Care (HPC)

 

Three Month Periods Ended

 

 

 

 

(in millions, except %)

 

March 29, 2026

 

March 30, 2025

 

Variance

Net sales

 

$

240.1

 

 

$

254.2

 

 

$

(14.1

)

 

(5.5

)%

Adjusted EBITDA

 

 

8.1

 

 

 

7.3

 

 

 

0.8

 

 

11.0

%

Adjusted EBITDA margin

 

 

3.4

%

 

 

2.9

%

 

 

50

bps

Net sales decreased 5.5%. Excluding favorable foreign currency impacts, organic net sales decreased 10.7%. Reported net sales in Personal Care were down low single digits and net sales in Home Appliances were down high single digits. Excluding the favorable impact of foreign currency, organic net sales in EMEA declined across both Home Appliances and Personal Care, impacted by elevated levels of inventory at a key retailer following soft consumer demand amid increased competition. LATAM organic net sales increased mid single digits due to sustained growth in Personal Care. North American net sales percent declined in the mid teens, primarily driven by lower volumes in light of increased product cost from higher tariffs and customer inventory management actions to address pockets of excess inventory.

Adjusted EBITDA was $8.1 million compared to $7.3 million in the prior year, and adjusted EBITDA margins increased to 3.4% compared to 2.9% last year, driven by pricing, reduced investment spend, cost improvement initiatives and favorable foreign exchange partially offset by lower volumes and higher tariff costs.

Liquidity and Debt

As of the end of the quarter, the Company had a cash balance of $125.1 million and total liquidity of $595.9 million, including undrawn capacity on its cash flow revolver of $470.8 million. The Company also had $599.7 million of debt outstanding, with $24.0 million of outstanding borrowings on the revolver, senior unsecured notes of $496.1 million and finance leases of $79.6 million. The Company ended the quarter with net debt of $474.6 million.

Fiscal 2026 Earnings Framework

The Company expects to deliver flat to low single digit growth in reported net sales in fiscal 2026. Fiscal 2026 adjusted EBITDA is expected to increase by low single digits. Adjusted free cash flow is expected to be approximately 50% of adjusted EBITDA.

The Company continues to target a long-term net leverage ratio of 2.0 – 2.5 times.

Conference Call/Webcast Scheduled for 9:00 A.M. Eastern Time Today

Spectrum Brands will host an earnings conference call and webcast at 9:00 a.m. Eastern Time today, May 7, 2026. The live webcast and related presentation slides will be available by visiting the Event Calendar page in the Investor Relations section of Spectrum Brands’ website at www.spectrumbrands.com. Participants may register here. Instructions will be provided to ensure the necessary audio applications are downloaded and installed. Users can obtain these at no charge.

A replay of the live broadcast will be accessible through the Event Calendar page in the Investor Relations section of the Company’s website.

About Spectrum Brands Holdings, Inc.

Spectrum Brands is a home-essentials company with a mission to make living better at home. We focus on delivering innovative products and solutions to consumers for use in and around the home through our trusted brands. We are a leading supplier of specialty pet supplies, lawn and garden and home pest control products, personal insect repellents, shaving and grooming products, personal care products, and small household appliances. Helping to meet the needs of consumers worldwide, we offer a broad portfolio of market-leading, well-known and widely trusted brands including Tetra®, DreamBone®, SmartBones®, Nature’s Miracle®, 8-in-1®, FURminator®, Healthy-Hide®, Good Boy®, Meowee!®, OmegaOne®, Spectracide®, Cutter®, Repel®, Hot Shot®, Rejuvenate®, Black Flag®, Liquid Fence®, Remington®, George Foreman®, Russell Hobbs®, Black + Decker®, PowerXL®, Emeril Lagasse®, and Copper Chef®. For more information, please visit www.spectrumbrands.com.Spectrum Brands – A Home Essentials Company™

Non-GAAP Measurements

Our consolidated results contain non-GAAP metrics such as organic net sales, adjusted EBITDA, adjusted EBITDA margin, adjusted EPS and adjusted Free Cash Flow. While we believe organic net sales and adjusted EBITDA, adjusted EBITDA margin, adjusted EPS and adjusted Free Cash Flow are useful supplemental information, such adjusted results are not intended to replace our financial results in accordance with Accounting Principles Generally Accepted in the United States (“GAAP”) and should be read in conjunction with those GAAP results.

Organic Net Sales – We define organic net sales as net sales excluding the effect of changes in foreign currency exchange rates and impact from acquisitions (where applicable). We believe this non-GAAP measure provides useful information to investors because it reflects regional and operating segment performance from our activities without the effect of changes in currency exchange rates and acquisitions. We use organic net sales as one measure to monitor and evaluate our regional and segment performance. Organic growth is calculated by comparing organic net sales to net sales in the prior year. The effect of changes in currency exchange rates is determined by translating the current period net sales using the currency exchange rates that were in effect during the prior comparative period. Net sales are attributed to the geographic regions based on the country of destination. We exclude net sales from acquired businesses in the current year for which there are no comparable sales in the prior period.

Adjusted EBITDA and Adjusted EBITDA Margin – Adjusted EBITDA and adjusted EBITDA margin are non-GAAP metrics used by management, which we believe are useful to investors to measure the operational strength and performance of our business. These metrics provide investors additional information about our operating profitability for certain non-cash items, non-routine items we do not expect to continue at the same level in the future, as well as other items not core to our continuing operations. By providing these measures, together with a reconciliation of the most directly comparable GAAP measure, we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives, as securities analysts and other interested parties use such calculations as a measure of financial performance and debt service capabilities, and they are regularly used by management and our Board of Directors for internal purposes in evaluating our business performance, making budgeting decisions, and comparing our performance against other peer companies using similar measures. They facilitate comparisons between peer companies since interest, taxes, depreciation, and amortization can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA is also used for determining compliance with the Company’s debt covenants. EBITDA is calculated by excluding the Company’s income tax expense, interest expense, depreciation expense and amortization expense (from intangible assets) from net income from continuing operations. Adjusted EBITDA also excludes certain non-cash adjustments including share based compensation; impairment charges on property, plant and equipment, right of use lease assets, and goodwill and other intangible assets; gain or loss from the early extinguishment of debt; and purchase accounting adjustments recognized in income subsequent to an acquisition attributable to the step-up in value on assets acquired. Additionally, the Company will further recognize adjustments from adjusted EBITDA for other costs, gains and losses that are considered significant, non-recurring, or otherwise not supporting the continuing operations and revenue generating activity of the segment or Company, including but not limited to, exit and disposal activities, or incremental costs associated with strategic transactions, restructuring and optimization initiatives such as the acquisition or divestiture of a business, related integration or separation costs, or the development and implementation of strategies to optimize or restructure the Company and its operations. Adjusted EBITDA margin is adjusted EBITDA as a percentage of reported net sales.

Adjusted EPS – Management uses adjusted EPS as one means of analyzing the Company’s current and future financial performance and identifying trends in its financial condition and results of operations. Management believes that adjusted EPS is a useful measure for providing further insight into our operating performance because it eliminates the effects of certain items that are not comparable from one period to the next. By providing these measures, together with a reconciliation of the most directly comparable GAAP measure, we believe we are enhancing investors’ understanding of our business and our results of operations, as well as assisting investors in evaluating how well we are executing our strategic initiatives, as securities analysts and other interested parties use such calculations as a measure of financial performance, and they are regularly used by management and our Board of Directors for internal purposes in evaluating our business performance, making budgeting decisions, and comparing our performance against other peer companies using similar measures. Adjusted EPS is calculated by excluding the effect of certain adjustments from diluted EPS, including non-cash adjustments including impairment charges on property, plant and equipment, operating and finance lease assets, and goodwill and other intangible assets; gain or loss from the early extinguishment of debt; and purchase accounting adjustments recognized in income subsequent to an acquisition attributable to the step-up in value on assets acquired. Additionally, the Company will further recognize adjustments from diluted EPS for other costs, gains and losses that are considered significant, non-recurring, or otherwise not supporting the continuing operations and revenue generating activity of the segment or Company, including but not limited to, exit and disposal activities, or incremental costs associated with strategic transactions, restructuring and optimization initiatives such as the acquisition or divestiture of a business, related integration or separation costs, or the development and implementation of strategies to optimize or restructure the Company and its operations. Adjusted EPS is further impacted by the effect on the income tax provision from adjustments made to reported diluted EPS.

Adjusted Free Cash Flow – Management uses adjusted free cash flow as a means of analyzing the Company’s operating results and evaluating cash flow generation from its revenue generating activities, excluding certain cash flow activity associated with strategic transactions and other costs and receipts attributable to non-recurring events. Management believes that adjusted free cash flow is a useful measure in understanding cash flow conversion associated with the Company’s operations that is available for acquisitions and other investments, service of debt, dividends and share repurchases and meetings its working capital requirements. By providing these measures, together with a reconciliation of the most directly comparable GAAP measure, we believe we are enhancing investors’ understanding of our business, as well as assisting investors in evaluating how well we are generating cash flow from operations, as securities analysts and other interested parties use such calculations as a measure of financial performance, and they are regularly used by management and our Board of Directors for internal purposes in evaluating our business performance, making budgeting decisions, and comparing our performance against other peer companies using similar measures. Free cash flow is calculated by excluding capital expenditures from cash flow provided (used) by operating activities and further adjusted for non-operating strategic transaction costs and other non-recurring or unusual cash flow activity that would otherwise be considered operating cash flow under US GAAP. Cash flow conversion is adjusted free cash flow as a percentage of adjusted EBITDA.

The Company provides this information to investors to assist in comparisons of past, present and future operating results and to assist in highlighting the results of on-going operations. While the Company’s management believes that non-GAAP measurements are useful supplemental information, such adjusted results are not intended to replace the Company’s GAAP financial results and should be read in conjunction with those GAAP results. Other Supplemental Information has been provided to demonstrate reconciliation of non-GAAP measurements discussed above to most relevant GAAP financial measurements.

Forward-Looking Statements

We have made or implied certain forward-looking statements in this document. Statements or expectations regarding our business and M&A strategy, macroeconomic headwinds, U.S. trade policy, our use of share repurchase plans, ERP platform transformation and productivity expectations, evaluating acquisition targets and entering into strategic partnerships, earnings framework, future operations and operating model, financial condition, estimated revenues, projected costs, inventory management, supply chain and supply chain relocation efforts, earnings power, project synergies, prospects, plans and strategic objectives of management, the geopolitical environment, and information concerning expected actions of third parties are forward-looking statements. When used in this report, the words future, anticipate, pro forma, seek, intend, plan, envision, estimate, believe, belief, expect, project, forecast, outlook, earnings framework, goal, target, could, would, will, can, should, may and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

Because these forward-looking statements are based upon our current expectations of future events and projections and are subject to a number of risks and uncertainties, many of which are beyond our control and some of which may change rapidly, actual results or outcomes may differ materially from those expressed or implied herein, and you should not place undue reliance on these statements. Important factors that could cause our actual results to differ materially from those expressed or implied herein include, without limitation: (1) the economic, social and political conditions, civil unrest, terrorist attacks, acts of war, natural disasters or other public health concerns in the U.S. or the international markets that impact our business, customers, employees (including our ability to retain and attract key personnel), manufacturing facilities, suppliers, capital markets or financial condition and results of operations, which may amplify the other risks and uncertainties we face; (2) the number of local, regional and global uncertainties could negatively impact our business; (3) the negative effect of the Russia-Ukraine war, the Israel-Hamas war, and the U.S.-Iran war and their impact on those regions and surrounding regions, including the Middle East and disruptions to international trade, supply chain and shipping routes and pricing, and on our operations and those operations of our customers, suppliers and other stakeholders; (4) our reliance on third-party partners, suppliers and distributors that are outside our control to achieve our business objectives; (5) the impact of government intervention with or influence on the operations of our suppliers, including in China; (6) the impact of expenses resulting from the implementation of new business strategies, divestitures or current and proposed restructuring and optimization activities, including changes in inventory and distribution center changes which are complicated and involve coordination among a number of stakeholders, including our suppliers and transportation and logistics handlers; (7) the impact of our indebtedness and financial leverage position on our business, financial condition and results of operations; (8) the impact of restrictions in our debt instruments on our ability to operate our business, finance our capital needs or pursue or expand business strategies; (9) any failure to comply with financial covenants and other provisions and restrictions of our debt instruments; (10) the effects of interest rate fluctuations or general economic conditions, including the impact of, uncertainty around and changes to, tariffs and trade policies, including the tariffs and trade agreements announced by the Trump Administration in 2025, the tariff refunds announced in 2026 and any further changes and that may be announced in the future, tariff mitigation efforts (including supply chain relocation efforts), inflation, recession or fears of a recession, depression or fears of a depression, labor costs and stock market volatility or monetary or fiscal policies in the countries where we do business; (11) the impact of fluctuations in transportation and shipment costs, fuel costs, commodity prices, costs or availability of raw materials or terms and conditions available from suppliers, including suppliers’ willingness to advance credit; (12) changes in foreign currency exchange rates that may impact our purchasing power, pricing and margin realization within international jurisdictions; (13) the loss of, significant reduction in, or dependence upon, sales to any significant retail customer(s), including their changes in retail inventory levels and management thereof; (14) competitive promotional activity or spending by competitors, or price reductions by competitors; (15) the introduction of new product features or technological developments by competitors and/or the development of new competitors or competitive brands, including via private label manufacturers; (16) changes in consumer spending preferences, shopping trends, and demand for our products, particularly in light of economic stress; (17) our ability to develop and successfully introduce new products, protect intellectual property and avoid infringing the intellectual property of third parties; (18) our ability to successfully identify, implement, achieve and sustain productivity improvements, cost efficiencies (including at our manufacturing and distribution operations) and cost savings; (19) the seasonal nature of sales of certain of our products; (20) the impact weather conditions may have on the sales of certain of our products; (21) our ability to respond to unusual weather activity, natural disasters and pandemics; (22) the cost and effect of unanticipated legal, tax or regulatory proceedings or new laws or regulations (including environmental, public health and consumer protection regulations); (23) our ability to use social media platforms as effective marketing tools and to manage negative commentary regarding us, and the impact of rules governing the use of e-commerce and social media; (24) public perception regarding the safety of products that we manufacture and sell, including the potential for environmental liabilities, product liability claims, litigation and other claims related to products manufactured by us and third parties; (25) the impact of existing, pending or threatened litigation, government regulation or other requirements or operating standards applicable to our business; (26) the impact of cybersecurity breaches or our actual or perceived failure to protect company and personal data, including our failure to comply with new and increasingly complex global data privacy regulations; (27) changes in accounting policies applicable to our business; (28) our discretion to adopt, conduct, suspend or discontinue any share repurchase program or conduct any debt repayments, redemptions, repurchases or refinancing transactions (including our discretion to conduct purchases or repurchases, if any, in a variety of manners including open-market purchases, privately negotiated transactions, tender offers, redemptions, or otherwise); (29) our ability to utilize net operating loss carry-forwards to offset tax liabilities; (30) our ability to separate the Company’s HPC business and create an independent Global Appliances business on expected terms, and within the anticipated time period, or at all, and to realize the potential benefits of such business; (31) our ability to create a pure play consumer products company composed of our GPC and H&G businesses and to realize the expected benefits of such creation, and within the anticipated time period, or at all; (32) our ability to successfully implement and realize the benefits of acquisitions or dispositions and the impact of any such transactions on our financial performance; (33) the impact of actions taken by significant shareholders; (34) the unanticipated loss of key members of senior management and the transition of new members of our management teams to their new roles; and (35) the other risk factors set forth in Spectrum Brands Holdings, Inc. 2025 Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and the other filings within the U.S. Securities and Exchange Commission (the “SEC”).

Some of the above-mentioned factors are described in further detail in the sections entitled Risk Factors in our annual and quarterly reports (including this report), as applicable. You should assume the information appearing in this report is accurate only as of the date hereof, or as otherwise specified, as our business, financial condition, results of operations and prospects may have changed since that date. Except as required by applicable law, including the securities laws of the U.S. and the rules and regulations of the SEC, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.

SPECTRUM BRANDS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited)

 

 

Three Month Periods Ended

 

Six Month Periods Ended

(in millions, except per share amounts)

 

March 29, 2026

 

March 30, 2025

 

March 29, 2026

 

March 30, 2025

Net sales

 

$

708.9

 

 

$

675.7

 

 

$

1,385.9

 

 

$

1,375.9

 

Cost of goods sold

 

 

438.6

 

 

 

422.3

 

 

 

874.0

 

 

 

864.7

 

Gross profit

 

 

270.3

 

 

 

253.4

 

 

 

511.9

 

 

 

511.2

 

Selling, general & administrative

 

 

226.8

 

 

 

218.2

 

 

 

441.3

 

 

 

431.3

 

Impairment of intangible assets

 

 

 

 

 

15.7

 

 

 

 

 

 

15.7

 

Total operating expenses

 

 

226.8

 

 

 

233.9

 

 

 

441.3

 

 

 

447.0

 

Operating income

 

 

43.5

 

 

 

19.5

 

 

 

70.6

 

 

 

64.2

 

Interest expense

 

 

7.3

 

 

 

7.5

 

 

 

14.1

 

 

 

13.7

 

Interest income

 

 

(0.5

)

 

 

(0.4

)

 

 

(1.1

)

 

 

(3.0

)

Other non-operating (income) expense, net

 

 

(0.1

)

 

 

1.0

 

 

 

0.3

 

 

 

5.7

 

Income from continuing operations before income taxes

 

 

36.8

 

 

 

11.4

 

 

 

57.3

 

 

 

47.8

 

Income tax expense

 

 

14.3

 

 

 

9.6

 

 

 

5.4

 

 

 

21.4

 

Net income from continuing operations

 

 

22.5

 

 

 

1.8

 

 

 

51.9

 

 

 

26.4

 

Loss from discontinued operations, net of tax

 

 

(0.4

)

 

 

(0.6

)

 

 

(1.4

)

 

 

(1.4

)

Net income

 

 

22.1

 

 

 

1.2

 

 

 

50.5

 

 

 

25.0

 

Net income from continuing operations attributable to non-controlling interest

 

 

 

 

 

0.3

 

 

 

 

 

 

0.6

 

Net income attributable to controlling interest

 

$

22.1

 

 

$

0.9

 

 

$

50.5

 

 

$

24.4

 

Amounts attributable to controlling interest

 

 

 

 

 

 

 

 

Net income from continuing operations attributable to controlling interest

 

$

22.5

 

 

$

1.5

 

 

$

51.9

 

 

$

25.8

 

Loss from discontinued operations attributable to controlling interest, net of tax

 

 

(0.4

)

 

 

(0.6

)

 

 

(1.4

)

 

 

(1.4

)

Net income attributable to controlling interest

 

$

22.1

 

 

$

0.9

 

 

$

50.5

 

 

$

24.4

 

Earnings Per Share

 

 

 

 

 

 

 

 

Basic earnings per share from continuing operations

 

$

0.97

 

 

$

0.06

 

 

$

2.22

 

 

$

0.96

 

Basic earnings per share from discontinued operations

 

 

(0.02

)

 

 

(0.03

)

 

 

(0.06

)

 

 

(0.06

)

Basic earnings per share

 

$

0.95

 

 

$

0.03

 

 

$

2.16

 

 

$

0.90

 

Diluted earnings per share from continuing operations

 

$

0.96

 

 

$

0.06

 

 

$

2.22

 

 

$

0.95

 

Diluted earnings per share from discontinued operations

 

 

(0.02

)

 

 

(0.03

)

 

 

(0.06

)

 

 

(0.05

)

Diluted earnings per share

 

$

0.94

 

 

$

0.03

 

 

$

2.16

 

 

$

0.90

 

Weighted Average Shares Outstanding

 

 

 

 

 

 

 

 

Basic

 

 

23.2

 

 

 

26.1

 

 

 

23.3

 

 

 

27.0

 

Diluted

 

 

23.3

 

 

 

26.2

 

 

 

23.4

 

 

 

27.1

 

SPECTRUM BRANDS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited)

 

 

Six Month Periods Ended

(in millions)

 

March 29, 2026

 

March 30, 2025

Cash flows from operating activities

 

 

 

 

Net cash provided (used) by operating activities from continuing operations

 

$

77.9

 

 

$

(48.6

)

Net cash used by operating activities from discontinued operations

 

 

(0.3

)

 

 

(0.7

)

Net cash provided (used) by operating activities

 

 

77.6

 

 

 

(49.3

)

Cash flows from investing activities

 

 

 

 

Purchases of property, plant and equipment

 

 

(17.4

)

 

 

(15.1

)

Other investing activity

 

 

 

 

 

(0.1

)

Net cash used by investing activities

 

 

(17.4

)

 

 

(15.2

)

Cash flows from financing activities

 

 

 

 

Payment of debt and debt premium

 

 

(6.2

)

 

 

(5.1

)

Proceeds from issuance of debt

 

 

24.0

 

 

 

83.0

 

Payment of debt issuance costs

 

 

 

 

 

(0.1

)

Dividends paid to shareholders

 

 

(21.8

)

 

 

(25.3

)

Dividends paid by subsidiary to non-controlling interest

 

 

 

 

 

(0.7

)

Treasury stock purchases

 

 

(42.3

)

 

 

(232.8

)

Excise tax paid on net share repurchases

 

 

(3.2

)

 

 

(9.7

)

Share based award tax withholding payments, net of proceeds upon vesting

 

 

(8.5

)

 

 

(4.4

)

Other financing activity

 

 

 

 

 

0.1

 

Net cash used by financing activities

 

 

(58.0

)

 

 

(195.0

)

Effect of exchange rate changes on cash and cash equivalents

 

 

(0.8

)

 

 

(12.8

)

Net change in cash, cash equivalents and restricted cash

 

 

1.4

 

 

 

(272.3

)

Cash, cash equivalents, and restricted cash, beginning of period

 

 

127.2

 

 

 

370.5

 

Cash, cash equivalents, and restricted cash, end of period

 

$

128.6

 

 

$

98.2

 

SPECTRUM BRANDS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Unaudited)

 

(in millions)

 

March 29, 2026

 

September 30,

2025

Assets

 

 

 

 

Cash and cash equivalents

 

$

125.1

 

$

123.6

Trade receivables, net

 

 

560.5

 

 

521.7

Other receivables

 

 

58.9

 

 

50.9

Inventories

 

 

487.1

 

 

446.1

Prepaid expenses and other current assets

 

 

40.3

 

 

41.9

Total current assets

 

 

1,271.9

 

 

1,184.2

Property, plant and equipment, net

 

 

242.5

 

 

255.0

Operating lease assets

 

 

118.6

 

 

73.5

Deferred charges and other

 

 

61.2

 

 

62.5

Goodwill

 

 

865.4

 

 

866.8

Intangible assets, net

 

 

914.3

 

 

937.6

Total assets

 

$

3,473.9

 

$

3,379.6

Liabilities and Shareholders’ Equity

 

 

 

 

Current portion of long-term debt

 

$

12.0

 

$

11.7

Accounts payable

 

 

348.7

 

 

283.7

Accrued wages and salaries

 

 

42.8

 

 

50.2

Accrued interest

 

 

4.9

 

 

4.5

Income tax payable

 

 

17.2

 

 

21.2

Short-term operating lease liabilities

 

 

20.9

 

 

31.8

Other current liabilities

 

 

107.8

 

 

120.1

Total current liabilities

 

 

554.3

 

 

523.2

Long-term debt, net of current portion

 

 

575.9

 

 

556.2

Long-term operating lease liabilities

 

 

116.7

 

 

54.5

Deferred income taxes

 

 

136.8

 

 

136.6

Uncertain tax benefit obligation

 

 

171.9

 

 

180.3

Other long-term liabilities

 

 

17.6

 

 

19.1

Total liabilities

 

 

1,573.2

 

 

1,469.9

Shareholders’ equity

 

 

1,900.7

 

 

1,909.7

Total liabilities and shareholders’ equity

 

$

3,473.9

 

$

3,379.6

SPECTRUM BRANDS HOLDINGS, INC.

OTHER SUPPLEMENTAL INFORMATION (Unaudited)

 

NET SALES AND ORGANIC NET SALES

 

The following is a summary of net sales by segment for the three and six month periods ended March 29, 2026 and March 30, 2025, respectively.

 

(in millions, except %)

 

Three Month Periods Ended

 

 

 

 

 

Six Month Periods Ended

 

 

 

 

 

March 29, 2026

 

March 30, 2025

 

Variance

 

March 29, 2026

 

March 30, 2025

 

Variance

GPC

 

$

299.3

 

$

269.2

 

$

30.1

 

 

11.2

%

 

$

580.9

 

$

529.2

 

$

51.7

 

 

9.8

%

H&G

 

 

169.5

 

 

152.3

 

 

17.2

 

 

11.3

%

 

 

243.4

 

 

244.4

 

 

(1.0

)

 

(0.4

)%

HPC

 

 

240.1

 

 

254.2

 

 

(14.1

)

 

(5.5

)%

 

 

561.6

 

 

602.3

 

 

(40.7

)

 

(6.8

)%

Net Sales

 

$

708.9

 

$

675.7

 

 

33.2

 

 

4.9

%

 

$

1,385.9

 

$

1,375.9

 

 

10.0

 

 

0.7

%

The following is a reconciliation of reported sales to organic sales for the three and six month periods ended March 29, 2026 compared to reported net sales for the three and six month periods ended March 30, 2025, respectively.

 

 

 

 

 

 

 

 

 

 

March 29, 2026

 

Net Sales

March 30, 2025

 

 

 

 

Three Month Periods Ended

(in millions, except %)

 

Net Sales

 

Effect of Changes in Foreign Currency

 

Organic Net Sales

 

 

Variance

GPC

 

$

299.3

 

$

(9.7

)

 

$

289.6

 

$

269.2

 

$

20.4

 

 

7.6

%

H&G

 

 

169.5

 

 

(0.1

)

 

 

169.4

 

 

152.3

 

 

17.1

 

 

11.2

%

HPC

 

 

240.1

 

 

(13.1

)

 

 

227.0

 

 

254.2

 

 

(27.2

)

 

(10.7

)%

Total

 

$

708.9

 

$

(22.9

)

 

$

686.0

 

$

675.7

 

 

10.3

 

 

1.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 29, 2026

 

Net Sales

March 30, 2025

 

 

 

 

Six Month Periods Ended

(in millions, except %)

 

Net Sales

 

Effect of Changes in Foreign Currency

 

Organic Net Sales

 

 

Variance

GPC

 

$

580.9

 

$

(16.1

)

 

$

564.8

 

$

529.2

 

$

35.6

 

 

6.7

%

H&G

 

 

243.4

 

 

(0.1

)

 

 

243.3

 

 

244.4

 

 

(1.1

)

 

(0.5

)%

HPC

 

 

561.6

 

 

(25.2

)

 

 

536.4

 

 

602.3

 

 

(65.9

)

 

(10.9

)%

Total

 

$

1,385.9

 

$

(41.4

)

 

$

1,344.5

 

$

1,375.9

 

 

(31.4

)

 

(2.3

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

SPECTRUM BRANDS HOLDINGS, INC.

OTHER SUPPLEMENTAL INFORMATION (Unaudited)

 
ADJUSTED EBITDAANDADJUSTED EBITDA MARGIN

 

The following is a reconciliation of reported net income from continuing operations to adjusted EBITDA and adjusted EBITDA margin for the three and six month periods ended March 29, 2026 and March 30, 2025, respectively.

 

 

 

 

 

 

 

Three Month Periods Ended

 

Six Month Periods Ended

(in millions, except %)

 

March 29, 2026

 

March 30, 2025

 

March 29, 2026

 

March 30, 2025

Net income from continuing operations

 

$

22.5

 

 

$

1.8

 

 

 

51.9

 

 

 

26.4

 

Income tax expense

 

 

14.3

 

 

 

9.6

 

 

 

5.4

 

 

 

21.4

 

Interest expense

 

 

7.3

 

 

 

7.5

 

 

 

14.1

 

 

 

13.7

 

Depreciation

 

 

13.9

 

 

 

14.0

 

 

 

29.5

 

 

 

28.0

 

Amortization

 

 

10.3

 

 

 

10.5

 

 

 

20.5

 

 

 

21.0

 

Share based compensation

 

 

6.0

 

 

 

5.2

 

 

 

10.3

 

 

 

9.9

 

Non-cash impairment charges

 

 

 

 

 

15.7

 

 

 

0.5

 

 

 

15.7

 

Exit and disposal costs

 

 

3.8

 

 

 

3.5

 

 

 

4.9

 

 

 

4.0

 

Global ERP transformation1

 

 

2.4

 

 

 

2.3

 

 

 

4.8

 

 

 

4.8

 

Litigation costs2

 

 

0.7

 

 

 

0.8

 

 

 

1.6

 

 

 

1.6

 

Other3

 

 

2.8

 

 

 

0.4

 

 

 

3.1

 

 

 

2.6

 

Adjusted EBITDA

 

$

84.0

 

 

$

71.3

 

 

$

146.6

 

 

$

149.1

 

Net sales

 

$

708.9

 

 

$

675.7

 

 

$

1,385.9

 

 

$

1,375.9

 

Net income from continuing operations margin

 

 

3.2

%

 

 

0.3

%

 

 

3.7

%

 

 

1.9

%

Adjusted EBITDA margin

 

 

11.8

%

 

 

10.6

%

 

 

10.6

%

 

 

10.8

%

____________________

1

Costs attributable to a multi-year transformation project to upgrade and implement our enterprise-wide operating systems to SAP S/4 HANA on a global basis, including project management and professional services for planning, design, and business process review that do not qualify as software configuration and implementation costs recognized as capital expenditures or deferred costs under applicable accounting principles. The Company had recently extended the project to include its HPC segment and anticipates costs to be incurred through further deployments through calendar year 2026.

2

Litigation costs are associated with the Company’s cost to facilitate various ongoing litigation matters associated with the Tristar Business acquisition in Fiscal 2023, previously disclosed in our 2025 Annual Report. Such costs are anticipated to be incurred until such litigation matters have been resolved.

3

Other is attributable to other project costs associated with previous strategic separation initiatives and distribution center transitions, plus certain non-recurring key executive severance costs in the prior year.

SPECTRUM BRANDS HOLDINGS, INC.

OTHER SUPPLEMENTAL INFORMATION (Unaudited)

 

ADJUSTED DILUTED EPS

 

The following is a reconciliation of reported diluted EPS from continuing operations to adjusted diluted EPS from continuing operations for the three and six month periods ended March 29, 2026 and March 30, 2025, respectively.

 

 

 

Three Month Periods Ended

 

Six Month Periods Ended

(per share amounts)

 

March 29, 2026

 

March 30, 2025

 

March 29, 2026

 

March 30, 2025

Diluted EPS from continuing operations

 

$

0.96

 

 

$

0.06

 

 

$

2.22

 

 

$

0.95

 

Adjustments:

 

 

 

 

 

 

 

 

Non-cash impairment charges

 

 

 

 

 

0.60

 

 

 

0.02

 

 

 

0.58

 

Exit and disposal costs

 

 

0.16

 

 

 

0.14

 

 

 

0.21

 

 

 

0.15

 

Global ERP transformation1

 

 

0.11

 

 

 

0.09

 

 

 

0.20

 

 

 

0.18

 

Litigation costs2

 

 

0.03

 

 

 

0.03

 

 

 

0.07

 

 

 

0.05

 

Other3

 

 

0.11

 

 

 

0.01

 

 

 

0.13

 

 

 

0.10

 

Pre-tax adjustments

 

 

0.41

 

 

 

0.87

 

 

 

0.63

 

 

 

1.06

 

Tax impact of adjustments4

 

 

(0.12

)

 

 

(0.25

)

 

 

(0.20

)

 

 

(0.30

)

Net adjustments

 

 

0.29

 

 

 

0.62

 

 

 

0.43

 

 

 

0.76

 

Diluted EPS from continuing operations, as adjusted

 

$

1.25

 

 

$

0.68

 

 

$

2.65

 

 

$

1.71

 

____________________

1

Costs attributable to a multi-year transformation project to upgrade and implement our enterprise-wide operating systems to SAP S/4 HANA on a global basis, including project management and professional services for planning, design, and business process review that do not qualify as software configuration and implementation costs recognized as capital expenditures or deferred costs under applicable accounting principles. The Company had recently extended the project to include its HPC segment and anticipates costs to be incurred through further deployments through calendar year 2026.

2

Litigation costs are associated with the Company’s cost to facilitate various ongoing litigation matters associated with the Tristar Business acquisition in Fiscal 2023, previously disclosed in our 2025 Annual Report. Such costs are anticipated to be incurred until such litigation matters have been resolved.

3

Other is attributable to other project costs associated with previous strategic separation initiatives and distribution center transitions, plus certain non-recurring key executive severance costs in the prior year.

4

Income tax adjustment reflects the impact on the income tax provision from the adjustments to diluted EPS.

SPECTRUM BRANDS HOLDINGS, INC.

OTHER SUPPLEMENTAL INFORMATION (Unaudited)

 

ADJUSTED FREE CASH FLOW

 

The following is a reconciliation of reported operating cash flow from continuing operations to adjusted free cash flow for the six month periods ended March 29, 2026 and March 30, 2025, respectively.

 

 

 

Six Month Periods Ended

(in millions)

 

March 29, 2026

 

March 30, 2025

Net cash provided by operating activities from continuing operations

 

$

77.9

 

 

$

(48.6

)

Purchases of property, plant and equipment

 

 

(17.4

)

 

 

(15.1

)

Free cash flow

 

 

60.5

 

 

 

(63.7

)

Deal transaction costs1

 

 

 

 

 

5.9

 

Other2

 

 

0.1

 

 

 

(0.6

)

Adjusted free cash flow

 

$

60.6

 

 

$

(58.4

)

____________________

1

Incremental cash flow attributable to certain strategic transactions including previous separation initiatives.

2

Other is attributable to restricted cash balances which are considered a component of operating cash flow under US GAAP.

 

Investor/Media Contact:

Jen Schultz 314-253-5923

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Department Stores Other Retail Pets Specialty Home Goods Consumer Retail Supply Chain Management Online Retail

MEDIA:

Logo
Logo

Vontier Reports First Quarter Results and Reaffirms Full Year 2026 Guidance

Vontier Reports First Quarter Results and Reaffirms Full Year 2026 Guidance

First Quarter 2026 Results

  • Sales of $750.6 million, up 1.3% vs. prior year; Core sales up 1.7% year-over-year

  • GAAP diluted net EPS of $0.66; Adjusted diluted net EPS of $0.80

  • Operating cash flow was $46.5 million; Adjusted free cash flow was $28.0 million, representing 25% adjusted free cash flow conversion

2026 Outlook

  • Initiates Q2 2026 guidance for adjusted diluted net EPS of $0.78 to $0.81

  • Reaffirms FY 2026 guidance for adjusted diluted net EPS of $3.35 to $3.50

RALEIGH, N.C.–(BUSINESS WIRE)–
Vontier Corporation (NYSE: VNT), a leading global provider of critical technologies and solutions to connect, manage and scale the mobility ecosystem, today announced results for the first quarter ended April 3, 2026.

Reported sales in the first quarter increased 1.3% year-over-year to $750.6 million. Core sales increased 1.7% led by strong demand for convenience retail solutions including fueling and environmental systems and payment technologies. Operating profit of $134.8 million increased 3.6% from the prior year, and operating profit margin increased approximately 40 basis points, to 18.0%. Adjusted operating profit of $157.6 million decreased 1.9% from the prior year and adjusted operating profit margin decreased 70 basis points to 21.0%. Net earnings were $94.3 million, and adjusted net earnings were $113.6 million, resulting in GAAP diluted net earnings per share of $0.66 and adjusted diluted net earnings per share of $0.80.

“Vontier delivered solid Sales and Order growth to start the year, and we continue to see meaningful momentum in our Convenience Retail end market, reinforcing our confidence in the growth opportunity ahead,” said Mark Morelli, President and Chief Executive Officer. “Demand trends across our most important end markets remain constructive, and we are confident in our outlook for the full year. We are focused on disciplined execution and capital allocation as we work to deliver strong full-year performance and long-term shareholder value.”

Segment Results

Environmental & Fueling Solutions

Q1 2026

Q1 2025

Change

Sales ($M)

$344.8

$329.8

4.5%

Segment Operating Profit ($M)

$101.9

$97.5

4.5%

Segment Operating Profit Margin

29.6%

29.6%

flat

Environmental & Fueling Solutions reported sales increased 4.5% versus the prior year. Core sales increased 6.1%, led by strong demand for fuel dispensing equipment and aftermarket parts. Segment operating profit margin was flat on benefits from volume leverage and ongoing simplification initiatives, offset by unfavorable mix.

Mobility Technologies

Q1 2026

Q1 2025

Change

Sales(a)($M)

$269.3

$270.5

(0.4)%

Segment Operating Profit ($M)

$44.7

$51.9

(13.9)%

Segment Operating Profit Margin

16.6%

19.2%

-260bps

(a) Includes $16.4 million and $12.2 million of intersegment sales for Q1 2026 and Q1 2025, respectively, that are eliminated in consolidation.

Mobility Technologies reported sales decreased 0.4% versus the prior year. Core sales decreased 1.2% year-over-year, on strong demand for convenience retail payment and point-of-sale technologies, offset by lower shipments of vehicle identification solutions versus the prior year. Segment operating profit margin declined 260 basis points year-over-year as ongoing simplification initiatives were more than offset by higher R&D expense and unfavorable mix.

Repair Solutions

Q1 2026

Q1 2025

Change

Sales ($M)

$152.9

$153.0

(0.1)%

Segment Operating Profit ($M)

$30.4

$33.2

(8.4)%

Segment Operating Profit Margin

19.9%

21.7%

-180bps

Repair Solutionsreported and coresales declined 0.1% versus the prior year. Sales at Repair Solutions held flat as growth initiatives helped offset macroeconomic pressures impacting service technicians’ discretionary spending. Segment operating profit margin declined 180 basis points on unfavorable mix and a reserve for bad debt.

Other Items

  • Announced an agreement to divest a majority of Teletrac Navman for a purchase price that values the business at $220 million.

  • Repurchased 1.8 million shares for $70 million during the quarter

  • Refinanced $500 million bond maturity; Repaid $200 million using cash on hand and refinanced the remaining $300 million with a 364-day term loan

  • Net leverage ratio ended Q1 at 2.4X

2026 Outlook

  • Underlying fundamentals in previous guidance unchanged; Total Sales and Adjusted Operating Margin revised to reflect the impact of the Teletrac divestiture (expected to close in early June)

  • Total sales of $2,990 to $3,040 million (including $110 million headwind from divestiture); Core sales growth midpoint of approximately 3%

  • Adjusted operating profit margin expansion midpoint of approximately 130bps year-over-year (including 50 basis point tailwind from divestiture)

  • Adjusted diluted net EPS in the range of $3.35 to $3.50

  • Adjusted free cash flow conversion of approximately 95%

Q2 2026 Outlook

  • Total sales of $730 to $740 million (including $15 million headwind from divestiture); Core sales growth down approximately 1%

  • Adjusted operating profit margin expansion of approximately 80 basis points (including 20 basis point tailwind from divestiture)

  • Adjusted diluted net EPS in the range of $0.78 to $0.81 (including $0.01 headwind from divestiture)

Conference Call Details

Vontier will discuss results and outlook during its quarterly investor conference call today starting at 8:30 a.m. ET. The call and an accompanying slide presentation will be webcast on the “Investors” section of Vontier’s website, www.vontier.com, under “Events & Presentations.” A replay of the webcast will be available at the same location shortly after the conclusion of the presentation.

The call can be accessed via webcast or by dialing +1 800-549-8228, along with the conference ID: 57509. A replay of the webcast will be available at the same location shortly after the conclusion of the presentation, or by dialing +1 888-660-6264, along with the passcode 57509 or under the “Investors” section of the Vontier website under “Events & Presentations.”

ABOUT VONTIER

Vontier (NYSE: VNT) is a global industrial technology company uniting productivity, automation and multi-energy technologies to meet the needs of a rapidly evolving, more connected mobility ecosystem. Leveraging leading market positions, decades of domain expertise and unparalleled portfolio breadth, Vontier powers the way the world moves – delivering smart, safe and sustainable solutions to our customers and the planet. Vontier has a culture of continuous improvement and innovation built upon the foundation of the Vontier Business System and embraced by colleagues worldwide. Additional information about Vontier is available on the Company’s website at www.vontier.com.

NON-GAAP FINANCIAL MEASURES

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also references “core sales growth,” “adjusted operating profit,” “adjusted operating profit margin,” “adjusted net earnings,” “adjusted diluted net earnings per share,” “free cash flow,” “adjusted free cash flow”, “adjusted free cash flow conversion,” “EBITDA,” “adjusted EBITDA,” “net debt,” and “net leverage ratio” which are non-GAAP financial measures. The reasons why we believe these measures, when used in conjunction with the GAAP financial measures, provide useful information to investors, how management uses such non-GAAP financial measures, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these measures are included in the supplemental reconciliation schedule attached. The non-GAAP financial measures should not be considered in isolation or as a substitute for the GAAP financial measures, but should instead be read in conjunction with the GAAP financial measures. The non-GAAP financial measures used by Vontier in this release may be different from similarly-titled non-GAAP measures used by other companies.

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of the federal securities laws. These statements include, but are not limited to statements regarding Vontier Corporation’s (the “Company’s”) business and acquisition opportunities, anticipated sales growth, anticipated adjusted operating margin expansion, anticipated adjusted net earnings per share, anticipated adjusted cash flow conversion, and anticipated earnings growth, and any other statements identified by their use of words like “anticipate,” “expect,” “believe,” “outlook,” “guidance,” or “will” or other words of similar meaning. There are a number of important risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These risks and uncertainties include, among other things, deterioration of or instability in the economy, the markets we serve, changes in U.S. and international geopolitics, including trade policies, volatility in financial markets, contractions or lower growth rates and cyclicality of markets we serve, competition, changes in industry standards and governmental policies and regulations that may adversely impact demand for our products or our costs, our ability to successfully identify, consummate, integrate and realize the anticipated value of appropriate acquisitions and successfully complete divestitures and other dispositions, our ability to develop and successfully market new products, software, and services and expand into new markets, the potential for improper conduct by our employees, agents or business partners, impact of divestitures, contingent liabilities relating to acquisitions and divestitures, impact of changes to tax laws, our compliance with changes in applicable laws and regulations, risks relating to global economic, political, war or hostility, public health, legal, compliance and business factors, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, the impact of our debt obligations on our operations, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, our ability to adequately protect our intellectual property rights, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, security breaches or other disruptions of our information technology systems, adverse effects of restructuring activities, impact of changes to U.S. GAAP, labor matters, and disruptions relating to man-made and natural disasters. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for the year ended December 31, 2025. These forward-looking statements represent Vontier’s beliefs and assumptions only as of the date of this release and Vontier does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

 

VONTIER CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in millions)

(unaudited)

 

 

April 3, 2026

 

December 31, 2025

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

233.8

 

 

$

492.2

 

Accounts receivable, net

 

529.6

 

 

 

527.4

 

Inventories

 

341.5

 

 

 

326.5

 

Prepaid expenses and other current assets

 

161.8

 

 

 

145.7

 

Total current assets

 

1,266.7

 

 

 

1,491.8

 

Property, plant and equipment, net

 

135.3

 

 

 

129.5

 

Operating lease right-of-use assets

 

33.4

 

 

 

34.4

 

Long-term financing receivables, net

 

288.0

 

 

 

285.0

 

Other intangible assets, net

 

395.4

 

 

 

412.4

 

Goodwill

 

1,757.0

 

 

 

1,757.6

 

Other assets

 

255.5

 

 

 

258.1

 

Total assets

$

4,131.3

 

 

$

4,368.8

 

LIABILITIES AND EQUITY

 

 

 

Current liabilities:

 

 

 

Short-term borrowings and current portion of long-term debt

$

305.6

 

 

$

502.2

 

Trade accounts payable

 

366.8

 

 

 

361.6

 

Current operating lease liabilities

 

13.8

 

 

 

14.3

 

Accrued expenses and other current liabilities

 

344.8

 

 

 

410.4

 

Total current liabilities

 

1,031.0

 

 

 

1,288.5

 

Long-term operating lease liabilities

 

24.0

 

 

 

24.8

 

Long-term debt

 

1,594.7

 

 

 

1,594.2

 

Other long-term liabilities

 

216.1

 

 

 

210.1

 

Total liabilities

 

2,865.8

 

 

 

3,117.6

 

Commitments and Contingencies

 

 

 

Equity:

 

 

 

Preferred stock

 

 

 

 

 

Common stock

 

 

 

 

 

Treasury stock

 

(1,000.3

)

 

 

(929.8

)

Additional paid-in capital

 

111.1

 

 

 

111.7

 

Retained earnings

 

2,021.3

 

 

 

1,930.5

 

Accumulated other comprehensive income

 

126.5

 

 

 

131.8

 

Total Vontier stockholders’ equity

 

1,258.6

 

 

 

1,244.2

 

Noncontrolling interests

 

6.9

 

 

 

7.0

 

Total equity

 

1,265.5

 

 

 

1,251.2

 

Total liabilities and equity

$

4,131.3

 

 

$

4,368.8

 

 

VONTIER CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS

(in millions, except per share amounts)

(unaudited)

 

 

Three Months Ended

 

April 3, 2026

 

March 28, 2025

Sales

$

750.6

 

 

$

741.1

 

Operating costs and expenses:

 

 

 

Cost of sales, excluding amortization of acquisition-related intangible assets

 

(398.3

)

 

 

(390.9

)

Selling, general and administrative expenses

 

(159.0

)

 

 

(160.3

)

Research and development expenses

 

(41.4

)

 

 

(40.2

)

Amortization of acquisition-related intangible assets

 

(17.1

)

 

 

(19.6

)

Operating profit

 

134.8

 

 

 

130.1

 

Non-operating income (expense), net:

 

 

 

Interest expense, net

 

(13.7

)

 

 

(15.1

)

Other non-operating expense, net

 

 

 

 

(3.9

)

Earnings before income taxes

 

121.1

 

 

 

111.1

 

Provision for income taxes

 

(26.8

)

 

 

(23.2

)

Net earnings

$

94.3

 

 

$

87.9

 

 

 

 

 

Net earnings per share:

 

 

 

Basic

$

0.67

 

 

$

0.59

 

Diluted

$

0.66

 

 

$

0.59

 

Weighted average shares outstanding:

 

 

 

Basic

 

141.8

 

 

 

149.0

 

Diluted

 

142.5

 

 

 

149.5

 

 
 

VONTIER CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)

 

Three Months Ended

 

April 3, 2026

 

March 28, 2025

Cash flows from operating activities:

 

 

 

Net earnings

$

94.3

 

 

$

87.9

 

Non-cash items:

 

 

 

Depreciation expense

 

14.8

 

 

 

12.9

 

Amortization of acquisition-related intangible assets

 

17.1

 

 

 

19.6

 

Stock-based compensation expense

 

7.7

 

 

 

7.5

 

Change in deferred income taxes

 

4.3

 

 

 

(5.7

)

Other non-cash items

 

0.4

 

 

 

11.0

 

Change in accounts receivable and long-term financing receivables, net

 

(7.3

)

 

 

3.3

 

Change in other operating assets and liabilities

 

(84.8

)

 

 

(26.1

)

Net cash provided by operating activities

 

46.5

 

 

 

110.4

 

Cash flows from investing activities:

 

 

 

Payments for additions to property, plant and equipment

 

(21.7

)

 

 

(17.7

)

Cash paid for equity investments

 

(0.3

)

 

 

 

Proceeds from sale of equity investments

 

1.0

 

 

 

 

Net cash used in investing activities

 

(21.0

)

 

 

(17.7

)

Cash flows from financing activities:

 

 

 

Proceeds from issuance of short-term debt

 

300.0

 

 

 

 

Proceeds from issuance of long-term debt

 

 

 

 

83.3

 

Repayment of long-term debt

 

(500.0

)

 

 

(133.3

)

Net proceeds from short-term borrowings

 

3.6

 

 

 

 

Payments for debt issuance costs

 

(0.4

)

 

 

(2.3

)

Payments of common stock cash dividend

 

(3.5

)

 

 

(3.7

)

Purchases of treasury stock

 

(70.0

)

 

 

(55.0

)

Proceeds from stock option exercises

 

2.2

 

 

 

1.9

 

Other financing activities

 

(13.1

)

 

 

(10.6

)

Net cash used in financing activities

 

(281.2

)

 

 

(119.7

)

Effect of exchange rate changes on cash and cash equivalents

 

(2.7

)

 

 

4.2

 

Net change in cash and cash equivalents

 

(258.4

)

 

 

(22.8

)

Beginning balance of cash and cash equivalents

 

492.2

 

 

 

356.4

 

Ending balance of cash and cash equivalents

$

233.8

 

 

$

333.6

 

 

VONTIER CORPORATION AND SUBSIDIARIES

SEGMENT FINANCIAL SUMMARY

(in millions)

(unaudited)

 

 

Three Months Ended

 

April 3, 2026

 

March 28, 2025

Sales

 

 

 

Environmental & Fueling Solutions

$

344.8

 

 

$

329.8

 

Mobility Technologies

 

269.3

 

 

 

270.5

 

Repair Solutions

 

152.9

 

 

 

153.0

 

Intersegment eliminations

 

(16.4

)

 

 

(12.2

)

Total Vontier Sales

$

750.6

 

 

$

741.1

 

 

 

 

 

Segment Operating Profit

 

 

 

Environmental & Fueling Solutions

$

101.9

 

 

$

97.5

 

Mobility Technologies

 

44.7

 

 

 

51.9

 

Repair Solutions

 

30.4

 

 

 

33.2

 

 

 

 

 

 

 

 

 

Segment Operating Profit Margin

 

 

 

Environmental & Fueling Solutions

 

29.6

%

 

 

29.6

%

Mobility Technologies

 

16.6

%

 

 

19.2

%

Repair Solutions

 

19.9

%

 

 

21.7

%

 

 

 

 

Operating Profit & Adjusted Operating Profit

 

 

 

Operating Profit (GAAP)

$

134.8

 

 

$

130.1

 

Operating Profit Margin (GAAP)

 

18.0

%

 

 

17.6

%

 

 

 

 

Adjusted Operating Profit (Non-GAAP)

$

157.6

 

 

$

160.6

 

Adjusted Operating Profit Margin (Non-GAAP)

 

21.0

%

 

 

21.7

%

 

VONTIER CORPORATION AND SUBSIDIARIES

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

AND OTHER INFORMATION

Core Sales Growth

We define core sales growth as the change in total sales calculated according to GAAP but excluding (i) sales from acquired and certain divested businesses; (ii) the impact of currency translation; and (iii) certain other items.

  • References to sales attributable to acquisitions or acquired businesses refer to GAAP sales from acquired businesses recorded prior to the first anniversary of the acquisition less the amount of sales attributable to certain divested or exited businesses or product lines not considered discontinued operations.

  • The portion of sales attributable to the impact of currency translation is calculated as the difference between (a) the period-to-period change in sales (excluding sales from acquired businesses) and (b) the period-to-period change in sales, including foreign operations, (excluding sales from acquired businesses) after applying the current period foreign exchange rates to the prior year period.

  • The portion of sales attributable to other items is calculated as the impact of those items which are not directly correlated to core sales which do not have an impact on the current or comparable period.

Core sales growth should be considered in addition to, and not as a replacement for or superior to, total sales, and may not be comparable to similarly titled measures reported by other companies.

Management believes that reporting the non-GAAP financial measure of core sales growth provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our sales performance with our performance in prior and future periods and to our peers. We exclude the effect of acquisitions and certain divestiture-related items because the nature, size and number of such transactions can vary dramatically from period to period and between us and our peers. We exclude the effect of currency translation and certain other items from core sales because these items are either not under management’s control or relate to items not directly correlated to core sales growth. Management believes the exclusion of these items from core sales growth may facilitate assessment of underlying business trends and may assist in comparisons of long-term performance.

Adjusted Operating Profit and Adjusted Operating Profit Margin

Adjusted operating profit refers to operating profit calculated in accordance with GAAP, but excluding amortization of acquisition-related intangible assets, costs associated with restructurings including one-time termination benefits and related charges and impairment and other charges associated with facility closure, contract termination and other related activities, and the related impact of certain divested or exited businesses or product lines not considered discontinued operations (“Restructuring- and divestiture-related adjustments”), transaction- and deal-related costs, asbestos-related adjustments associated with certain divested businesses, one-time costs related to the separation, amortization of acquisition-related inventory fair value step-up, gains and losses on sale of property, and other charges which represent charges incurred that are not part of our core operating results (“Other charges”). Adjusted operating profit margin refers to adjusted operating profit divided by GAAP sales.

Adjusted Net Earnings and Adjusted Diluted Net Earnings per Share

Adjusted net earnings refers to net earnings calculated in accordance with GAAP, but excluding on a pretax basis amortization of acquisition-related intangible assets, Restructuring- and divestiture-related adjustments, transaction- and deal-related costs, asbestos-related adjustments associated with certain divested businesses, one-time costs related to the separation, amortization of acquisition-related inventory fair value step-up, gains and losses on sale of property, Other charges, non-cash write-offs of deferred financing costs, gains and losses on sale of businesses and gains and losses on investments, including the tax effect of these adjustments and other tax adjustments. The tax effect of such adjustments was calculated by applying our estimated adjusted effective tax rate to the pretax amount of each adjustment. Adjusted diluted net earnings per share refers to adjusted net earnings divided by the weighted average diluted shares outstanding.

Free Cash Flow, Adjusted Free Cash Flow and Adjusted Free Cash Flow Conversion

Free cash flow refers to cash flow from operations calculated according to GAAP but excluding capital expenditures. Adjusted free cash flow refers to free cash flow adjusted for cash received from the sale of property, plant and equipment and cash paid for Restructuring- and divestiture-related adjustments, transaction- and deal-related costs and Other charges. Adjusted free cash flow conversion refers to adjusted free cash flow divided by adjusted net earnings.

Net Leverage Ratio, EBITDA and Adjusted EBITDA

EBITDA refers to net earnings calculated in accordance with GAAP, excluding interest, taxes, depreciation and amortization of acquisition-related intangible assets. Adjusted EBITDA refers to EBITDA adjusted for Restructuring- and divestiture-related adjustments, transaction- and deal-related costs, asbestos-related adjustments associated with certain divested businesses, one-time costs related to the separation, amortization of acquisition-related inventory fair value step-up, gains and losses on sale of property, Other charges, non-cash write-offs of deferred financing costs, gains and losses on sale of businesses and gains and losses on investments. Net leverage ratio refers to net debt divided by Adjusted EBITDA.

Management believes that these non-GAAP financial measures provide useful information to investors by reflecting additional ways of viewing aspects of our operations that, when reconciled to the corresponding GAAP measure, help our investors to understand the long-term profitability trends of our business, and facilitate comparisons of our profitability to prior and future periods and to our peers.

These non-GAAP measures should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measures, and may not be comparable to similarly titled measures reported by other companies.

A reconciliation of each of the projected Core Sales Growth, Adjusted Operating Profit Margin, Adjusted Diluted Net Earnings Per Share and Adjusted Free Cash Flow Conversion, which are forward-looking non-GAAP financial measures, to the most directly comparable GAAP financial measure, is not provided because the company is unable to provide such reconciliation without unreasonable effort. The inability to provide each reconciliation is due to the unpredictability of the amounts and timing of events affecting the items we exclude from the non-GAAP measure.

Components of Sales Growth

 

% Change Three Months Ended April 3, 2026 vs. Comparable 2025 Period

 

Environmental & Fueling Solutions

 

Mobility Technologies

 

Repair Solutions

 

Total

Total Sales Growth (GAAP)

4.5%

 

(0.4)%

 

(0.1)%

 

1.3%

Core sales growth (Non-GAAP)

6.1%

 

(1.2)%

 

(0.1)%

 

1.7%

Acquisitions and divestitures (Non-GAAP)

(3.5)%

 

(1.5)%

 

—%

 

(2.1)%

Currency exchange rates (Non-GAAP)

1.9%

 

2.3%

 

—%

 

1.7%

 

Reconciliation of Operating Profit to Adjusted Operating Profit

 

Three Months Ended

$ in millions

April 3, 2026

 

March 28, 2025

Operating Profit (GAAP)

$

134.8

 

 

$

130.1

 

Amortization of acquisition-related intangible assets

 

17.1

 

 

 

19.6

 

Restructuring- and divestiture-related adjustments

 

4.8

 

 

 

10.9

 

Transaction- and deal-related costs

 

0.7

 

 

 

0.9

 

Asbestos-related adjustments

 

0.2

 

 

 

(0.7

)

Other charges

 

 

 

 

(0.2

)

Adjusted Operating Profit (Non-GAAP)

$

157.6

 

 

$

160.6

 

 

 

 

 

Operating Profit Margin (GAAP)

 

18.0

%

 

 

17.6

%

Adjusted Operating Profit Margin (Non-GAAP)

 

21.0

%

 

 

21.7

%

 

Reconciliation of Net Earnings to Adjusted Net Earnings

 

Three Months Ended

($ in millions)

April 3, 2026

 

March 28, 2025

Net Earnings (GAAP)

$

94.3

 

 

$

87.9

 

Amortization of acquisition-related intangible assets

 

17.1

 

 

 

19.6

 

Restructuring- and divestiture-related adjustments

 

4.8

 

 

 

10.9

 

Transaction- and deal-related costs

 

0.7

 

 

 

0.9

 

Asbestos-related adjustments

 

0.2

 

 

 

(0.7

)

Other charges

 

0.3

 

 

 

(0.2

)

Non-cash write-off of deferred financing costs

 

 

 

 

0.2

 

(Gain) loss on equity investments

 

(0.4

)

 

 

3.6

 

Tax effect of the Non-GAAP adjustments and other tax adjustments

 

(3.4

)

 

 

(7.3

)

Adjusted Net Earnings (Non-GAAP)

$

113.6

 

 

$

114.9

 

 

 

 

 

Diluted weighted average shares outstanding

 

142.5

 

 

 

149.5

 

 

 

 

 

Diluted Net Earnings Per Share (GAAP)

$

0.66

 

 

$

0.59

 

Adjusted Diluted Net Earnings Per Share (Non-GAAP)

$

0.80

 

 

$

0.77

 

 

Reconciliation of Operating Cash Flow to Free Cash Flow, Adjusted Free Cash Flow, and Adjusted Free Cash Flow Conversion

 

Three Months Ended

($ in millions)

April 3, 2026

 

March 28, 2025

Operating Cash Flow (GAAP)

$

46.5

 

 

$

110.4

 

Less: Purchases of property, plant & equipment (capital expenditures)

 

(21.7

)

 

 

(17.7

)

Free Cash Flow (Non-GAAP)

$

24.8

 

 

$

92.7

 

Restructuring- and divestiture-related adjustments

 

2.5

 

 

 

2.1

 

Transaction- and deal-related costs

 

0.7

 

 

 

0.8

 

Adjusted Free Cash Flow (Non-GAAP)

$

28.0

 

 

$

95.6

 

Adjusted Net Earnings (Non-GAAP)

$

113.6

 

 

$

114.9

 

Adjusted Free Cash Flow Conversion (Non-GAAP)

 

24.6

%

 

 

83.2

%

 

Net Leverage Ratio and Reconciliation from Net Earnings to EBITDA to Adjusted EBITDA

Total Debt

$

1,906.0

 

Less: Cash

 

(233.8

)

Net Debt

$

1,672.2

 

Adjusted EBITDA (Non-GAAP)

$

705.9

 

Net Leverage Ratio

 

2.4

 

 

 

Three Months Ended

 

LTM

($ in millions)

 

April 3, 2026

 

April 3, 2026

Net Earnings (GAAP)

 

$

94.3

 

 

$

412.5

 

Interest expense, net

 

 

13.7

 

 

 

58.4

 

Income tax expense

 

 

26.8

 

 

 

105.7

 

Depreciation and amortization expense

 

 

31.9

 

 

 

124.6

 

EBITDA (Non-GAAP)

 

$

166.7

 

 

$

701.2

 

Restructuring- and divestiture-related adjustments

 

 

4.8

 

 

 

11.4

 

Transaction- and deal-related costs

 

 

0.7

 

 

 

3.3

 

Asbestos-related adjustments

 

 

0.2

 

 

 

0.6

 

Other charges

 

 

0.3

 

 

 

(0.9

)

Gain on sale of businesses

 

 

 

 

 

(3.5

)

Gain on equity investments

 

 

(0.4

)

 

 

(6.2

)

Adjusted EBITDA (Non-GAAP)

 

$

172.3

 

 

$

705.9

 

 

INVESTOR RELATIONS:

Ryan Edelman

Vice President, Investor Relations

+1 (984) 238-1929

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Software Vehicle Technology Machinery Machine Tools, Metalworking & Metallurgy Fleet Management IOT (Internet of Things) General Automotive Aftermarket Technology Automotive Satellite Manufacturing

MEDIA:

Logo
Logo

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

– The Company Maintains Fiscal 2026 Guidance –

PIOMBINO DESE, Italy–(BUSINESS WIRE)–Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2026.

First Quarter of 2026 Highlights (comparisons to prior-year period)

  • For the first quarter of 2026, revenue increased 7% (10% on a constant currency basis) to €273.6 million, with high-value solutions representing 47% of total revenue.

  • Gross profit margin increased 30 basis points to 27.5%.

  • Adjusted EBITDA margin increased 150 basis points to 23.9%.

  • Diluted earnings per share were €0.10, and adjusted diluted earnings per share were €0.11.

  • The Company is maintaining its fiscal 2026 guidance and still expects revenue in the range of €1.26 billion to €1.29 billion, adjusted EBITDA in the range of €331.8 million to €346.9 million, and adjusted diluted EPS in the range of €0.59 to €0.63.

First Quarter 2026 Results

For the first quarter of 2026, total revenue increased 7% year-over-year (10% on a constant currency basis) to €273.6 million, driven by a 13% revenue increase (16% on a constant currency basis) from the Company’s Biopharmaceutical and Diagnostic Solutions (BDS) Segment, which offset the revenue decline from the Engineering Segment. Revenue from high-value solutions increased 17%, year-over-year, to €128.6 million, and represented 47% of total revenue for the first quarter of 2026.

In the first quarter of 2026, gross profit margin increased 30 basis points to 27.5% driven by: (i) the ongoing improvements in Fishers and Latina as the new facilities continue to scale, (ii) an increase in high-value solutions, and (iii) improved marginality in the Engineering Segment. These positive trends were partially offset by the expected higher depreciation and the effects of foreign currency translation in the first quarter of 2026. Operating profit margin improved 70 basis points to 14.2%.

Net profit was €28.0 million for the first quarter of 2026, with diluted earnings per share of €0.10. For the first quarter of 2026, adjusted net profit increased to €29.6 million and adjusted diluted earnings per share increased to €0.11, compared with €0.10 for the same period last year.

For the first quarter of 2026, adjusted EBITDA increased to €65.5 million, and adjusted EBITDA margin improved 150 basis points to 23.9%, compared with the same period last year.

Franco Stevanato, Chief Executive Officer, commented, “The first quarter was a solid start to 2026, highlighted by strong momentum in the BDS Segment which delivered 16% growth at constant currency rates, driven by revenue increases across most product categories in both high-value and standard products. As expected, higher depreciation tempered gross profit margins in the quarter but results also reflect financial improvements in Fishers and Latina as we scale production, which in turn is driving the increase in high-value solutions. Revenue from biologics, which is our fastest growing end market, increased 15%, compared to the prior-year period, driven by GLP1s which accounted for approximately 21% to 22% of total Company revenue. Our success in this blockbuster treatment class demonstrates the trust and reliability that customers place on Stevanato Group to deliver high quality products at scale for their most valuable drug assets.”

Biopharmaceutical and Diagnostic Solutions (BDS) Segment

Revenue grew 13% (16% on a constant currency basis) to €249.0 million for the first quarter of 2026, compared with the same period last year, driven by growth in high value and standard products.

In the first quarter of 2026, revenue from high-value solutions increased 17% to €128.6 million, and represented 52% of BDS Segment revenue, driven predominantly by high-performance syringes and, to a lesser extent, EZ-fill® vials. Revenue from other containment and delivery solutions increased 9% to €120.3 million, compared with the same period last year, driven mostly by standard syringes and cartridges, which offset a lower revenue from IVD services.

For the first quarter of 2026, gross profit increased €1.2 million driven by the ramp up in Fishers and Latina and the favorable mix shift in high-value solutions. This was partially offset by: (i) higher depreciation, which was the largest headwind to gross profit, as more manufacturing lines are put into commercial service, (ii) the unfavorable effects of foreign currency, (iii) lower revenue and profit from an accretive pilot project with an industry-leading customer for large-batch, Not for Human Use (NFHU) fill and finish services, which did not recur in the first quarter of 2026, and (iv) the unfavorable impact from tariffs. As a result, gross profit margin decreased 300 basis points to 28.3%.

Engineering Segment

Revenue from the Engineering Segment decreased 31% to €24.6 million for the first quarter of 2026, compared with the same period last year, driven by lower revenue from glass converting and assembly manufacturing, which offset growth in pharmaceutical visual inspection.

For the first quarter of 2026, gross profit margin for the Engineering Segment increased 460 basis points to 15.3%, compared with the same period last year, as the Company begins to realize the benefits from the actions taken under its business optimization plan. This includes right-sizing operations and an improved labor cost structure which led to better financial performance in the Company’s Denmark operations. While actions under the optimization plan are starting to gain traction, the Company remains cautious given the current slow pace of orders.

Balance Sheet and Cash Flow

As of March 31, 2026, the Company had cash and cash equivalents of €111.7 million, and net debt of €337.7 million.

For the first quarter of 2026, capital expenditures totaled €67.6 million, as the Company continues to increase capacity in its new manufacturing facilities in Indiana and Italy. For the three-months ended March 31, 2026, cash flow from operating activities was €75.5 million and cash used for the purchase of property, plant, and equipment, and intangible assets totaled €70.7 million. As a result, the Company generated €5.5 million of positive free cash flow for the first quarter of 2026.

The Company believes that it has adequate liquidity to fund its strategic priorities over at least the next twelve months through a combination of cash on hand, cash generated from operations, available credit lines, and the ability to access additional financing.

2026 Guidance

The Company is maintaining its fiscal 2026 guidance and continues to expect:

  • Revenue in the range of €1.26 billion to €1.29 billion;

  • Adjusted EBITDA in the range of €331.8 million to €346.9 million; and

  • Adjusted diluted EPS in the range of €0.59 to €0.63.

Franco Stevanato concluded, “Looking ahead, our strategic investments and focus on high-value, scalable solutions position us to capitalize on the accelerating growth in biologics and injectable therapies. With our operational flexibility and competitive leadership in core product categories, we are confident in our ability to support customers and drive future success.”

Conference call: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 7, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Investor Relations section of the Company’s website.

Pre-registration: Participants who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. We encourage participants to pre-register for the conference call using the following link: Pre-registration for STVN Q1 2026 earnings webcast.

Webcast: A live, listen-only webcast of the call will be available at the following link: STVN Q1 2026 webcast.

Dial in: Those who are unable to pre-register may dial in by calling:

Italy:

+39 02 802 09 11

United Kingdom:

+44 1 212 818004

United States:

+1 718 705 8796

United States Toll Free:

+1 855 265 6958

Questions during the call: Participants who wish to ask questions during the call should use the HD webphone link: STVN Q1 2026 Link for Questions

Replay: The webcast will be archived for three months on the Company’s Investor Relations section of its website.

Forward-Looking Statements

This press release may include forward-looking statements. The words “expects,” “scale,” “driving,” “increase,” “begins,” “are starting,” “remains,” “continues,” “believes,” “expect,” “position,” “accelerating,” “drive,” and other similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s future financial performance, including revenue, operating expenses and ability to maintain profitability, and operational and commercial capabilities; the Company’s expectations regarding the development of the industry and the competitive environment in which it operates; the expansion of the Company’s plants and sites, and our expectations related to our capacity expansion; the global supply chain and the Company’s committed orders; customer demand; the success of the Company’s initiatives to optimize the industrial footprint, harmonize processes and enhance supply chain and logistics strategies; the Company’s geographical and industrial footprint; and the Company’s goals, strategies, and investment plans. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future, and may cause the actual results, performance, or achievements of the Company to be materially different from those expressed or implied by such forward looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company’s ability to control or estimate precisely, such as conditions in the U.S. capital markets, negative global and domestic economic and political conditions, inflation, trade war and global tariff policies, the impact of the conflict between Russia and the Ukraine, the evolving events in Israel and Gaza, the Iran regional conflict (including U.S. participation), supply chain and logistical challenges and other factors such as the Company’s ability to continue to obtain financing to meet its liquidity needs, changes in the geopolitical, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. For a description of the risks that could cause the Company’s future results to differ from those expressed in any such forward looking statements, refer to the risk factors discussed in our most recent annual report on Form 20-F, and our most recent filings with the U.S. Securities and Exchange Commission. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the Company assumes no obligation to update any such forward-looking statements.

Non-GAAP Financial Information

This press release contains non-GAAP financial measures. Please refer to the tables included in this press release for a reconciliation of non-GAAP financial measures.

Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Operating Profit, Adjusted Operating Profit Margin, Adjusted Income Taxes, Adjusted Net Profit, Adjusted Diluted EPS, CAPEX, Free Cash Flow, Net Cash/(Debt), and Capital Employed. The Company believes that these non-GAAP financial measures provide useful and relevant information regarding its performance and improve its ability to assess our financial condition. While similar measures are widely used in the industry in which the Company operates, the financial measures it uses may not be comparable to other similarly titled measures used by other companies, nor are they intended to be substitutes for measures of financial performance or financial position as prepared in accordance with IFRS.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation, and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.

Consolidated Income Statement

(Amounts in € millions, except per share data)

 

 

 

For the three months

 

 

 

ended March 31,

 

 

 

 

 

 

 

2026

 

 

%

 

 

2025

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

 

273.6

 

 

 

100.0

%

 

 

256.6

 

 

 

100.0

%

Costs of sales

 

 

198.4

 

 

 

72.5

%

 

 

186.7

 

 

 

72.8

%

Gross Profit

 

 

75.2

 

 

 

27.5

%

 

 

69.9

 

 

 

27.2

%

Other operating Income

 

 

1.4

 

 

 

0.5

%

 

 

1.1

 

 

 

0.4

%

Selling and Marketing Expenses

 

 

6.7

 

 

 

2.5

%

 

 

6.0

 

 

 

2.3

%

Research and Development Expenses

 

 

5.8

 

 

 

2.1

%

 

 

5.9

 

 

 

2.3

%

General and Administrative Expenses

 

 

25.3

 

 

 

9.2

%

 

 

24.5

 

 

 

9.6

%

Operating Profit

 

 

38.7

 

 

 

14.2

%

 

 

34.6

 

 

 

13.5

%

Finance Income

 

 

3.4

 

 

 

1.2

%

 

 

6.0

 

 

 

2.2

%

Finance Expense

 

 

2.9

 

 

 

1.0

%

 

 

5.5

 

 

 

2.1

%

Profit Before Tax

 

 

39.2

 

 

 

14.3

%

 

 

35.1

 

 

 

13.7

%

Income Taxes

 

 

11.2

 

 

 

4.1

%

 

 

8.6

 

 

 

3.3

%

Net Profit

 

 

28.0

 

 

 

10.2

%

 

 

26.5

 

 

 

10.3

%

Earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

Basic earnings per ordinary share

 

 

0.10

 

 

 

 

 

 

0.10

 

 

 

 

Diluted earnings per ordinary share

 

 

0.10

 

 

 

 

 

 

0.10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average shares outstanding

 

 

273.0

 

 

 

 

 

 

272.9

 

 

 

 

Average shares assuming dilution

 

 

273.0

 

 

 

 

 

 

272.9

 

 

 

 

Reported Segment Information

(Amounts in € millions)

 

 

 

For the three months ended March 31, 2026

 

 

 

Biopharmaceutical

and Diagnostic

Solutions

 

 

Engineering

 

 

Adjustments,

eliminations

and

unallocated

items

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

249.0

 

 

 

24.6

 

 

 

 

 

 

273.6

 

Inter-Segment

 

 

0.3

 

 

 

31.0

 

 

 

(31.2

)

 

 

 

Revenue

 

 

249.2

 

 

 

55.6

 

 

 

(31.2

)

 

 

273.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

70.5

 

 

 

8.5

 

 

 

(3.9

)

 

 

75.2

 

Gross Profit Margin

 

 

28.3

%

 

 

15.3

%

 

 

 

 

 

27.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Profit

 

 

44.1

 

 

 

3.7

 

 

 

(9.1

)

 

 

38.7

 

Operating Profit Margin

 

 

17.7

%

 

 

6.6

%

 

 

 

 

 

14.2

%

 

 

For the three months ended March 31, 2025

 

 

 

Biopharmaceutical

and Diagnostic

Solutions

 

 

Engineering

 

 

Adjustments,

eliminations

and

unallocated

items

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External Customers

 

 

220.8

 

 

 

35.7

 

 

 

 

 

 

256.6

 

Inter-Segment

 

 

0.4

 

 

 

42.4

 

 

 

(42.8

)

 

 

 

Revenue

 

 

221.2

 

 

 

78.2

 

 

 

(42.8

)

 

 

256.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

69.3

 

 

 

8.3

 

 

 

(7.7

)

 

 

69.9

 

Gross Profit Margin

 

 

31.3

%

 

 

10.7

%

 

 

 

 

 

27.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Profit

 

 

41.5

 

 

 

3.7

 

 

 

(10.6

)

 

 

34.6

 

Operating Profit Margin

 

 

18.8

%

 

 

4.7

%

 

 

 

 

 

13.5

%

Cash Flow

(Amounts in € millions)

 

 

 

For the three months

ended March 31,

 

 

 

2026

 

 

2025

 

Cash flow from operating activities

 

 

75.5

 

 

 

99.8

 

Cash flow used in investing activities

 

 

(70.4

)

 

 

(70.7

)

Cash flow used in financing activities

 

 

(24.9

)

 

 

(35.7

)

Net change in cash and cash equivalents

 

 

(19.8

)

 

 

(6.6

)

Non-GAAP Financial Information

This press release contains non-GAAP financial measures. Please refer to “Non-GAAP Financial Information” and the tables included in this press release for a reconciliation of non-GAAP financial measures.

Reconciliation of Revenue to Constant Currency Revenue

(Amounts in € millions)

 

Three months ended March 31, 2026

 

Biopharmaceutical

and

Diagnostic

Solutions

 

 

Engineering

 

 

Consolidated

 

Reported Revenue (IFRS GAAP)

 

 

249.0

 

 

 

24.6

 

 

 

273.6

 

Effect of changes in currency translation rates

 

 

8.1

 

 

 

 

 

 

8.1

 

Constant Currency Revenue (Non-IFRS GAAP)

 

 

257.0

 

 

 

24.6

 

 

 

281.7

 

Reconciliation of EBITDA

(Amounts in € millions)

 

 

 

For the three months

ended March 31,

 

 

Change

 

 

 

2026

 

 

2025

 

 

%

 

Net Profit

 

 

28.0

 

 

 

26.5

 

 

 

5.7

%

Income Taxes

 

 

11.2

 

 

 

8.6

 

 

 

30.4

%

Finance Income

 

 

(3.4

)

 

 

(6.0

)

 

 

(43.6

)%

Finance Expenses

 

 

2.9

 

 

 

5.5

 

 

 

(47.8

)%

Operating Profit

 

 

38.7

 

 

 

34.6

 

 

 

11.9

%

Depreciation and Amortization and Impairment of PPE

 

 

24.7

 

 

 

20.6

 

 

 

19.5

%

EBITDA

 

 

63.4

 

 

 

55.3

 

 

 

14.7

%

Calculation of Net Profit Margin, Operating Profit Margin, Adjusted EBITDA Margin and Adjusted Operating Profit Margin

(Amounts in € millions)

 

 

 

For the three months

ended March 31,

 

 

 

2026

 

 

2025

 

Revenue

 

 

273.6

 

 

 

256.6

 

Net Profit Margin (Net Profit/ Revenue)

 

 

10.2

%

 

 

10.3

%

Operating Profit Margin (Operating Profit/ Revenue)

 

 

14.2

%

 

 

13.5

%

Adjusted EBITDA Margin (Adjusted EBITDA/ Revenue)

 

 

23.9

%

 

 

22.4

%

Adjusted Operating Profit Margin (Adjusted Operating Profit/ Revenue)

 

 

14.9

%

 

 

14.3

%

Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes,

Net Profit, and Diluted EPS

(Amounts in € millions, except per share data)

 

Three months ended March 31, 2026

 

EBITDA

 

 

Operating

Profit

 

 

Income

Taxes (3)

 

 

Net Profit

 

 

Diluted EPS

(EUR)

 

Reported

 

 

63.4

 

 

 

38.7

 

 

 

11.2

 

 

 

28.0

 

 

 

0.10

 

Adjusting items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Start-up costs new plants (1)

 

 

1.8

 

 

 

1.8

 

 

 

0.5

 

 

 

1.3

 

 

 

0.00

 

Restructuring and related charges (2)

 

 

0.3

 

 

 

0.3

 

 

 

0.1

 

 

 

0.2

 

 

 

0.00

 

Adjusted

 

 

65.5

 

 

 

40.8

 

 

 

11.8

 

 

 

29.6

 

 

 

0.11

 

Adjusted Margin

 

 

23.9

%

 

 

14.9

%

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2025

 

EBITDA

 

 

Operating

Profit

 

 

Income

Taxes (3)

 

 

Net Profit

 

 

Diluted EPS

(EUR)

 

Reported

 

 

55.3

 

 

 

34.6

 

 

 

8.6

 

 

 

26.5

 

 

 

0.10

 

Adjusting items:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Start-up costs new plants (1)

 

 

0.8

 

 

 

0.8

 

 

 

0.2

 

 

 

0.6

 

 

 

0.00

 

Restructuring and related charges (2)

 

 

1.3

 

 

 

1.3

 

 

 

0.3

 

 

 

1.0

 

 

 

0.00

 

Adjusted

 

 

57.4

 

 

 

36.7

 

 

 

9.1

 

 

 

28.1

 

 

 

0.10

 

Adjusted Margin

 

 

22.4

%

 

 

14.3

%

 

 

 

 

 

 

 

 

 

 

(1) During the three months ended March 31, 2026, and the three months ended March 31, 2025, the Group recorded €1.8 million and €0.8 million, respectively, of start-up costs for the new plants in Fishers, Indiana, United States, and in Latina, Italy. These costs are primarily related to labor costs for training and travel of personnel who are in the learning and development phase and not active in the manufacturing of products.

 

(2) During the three months ended March 31, 2026, and the three months ended March 31, 2025, the Group recorded €0.3 million and €1.3 million, respectively, of restructuring and related charges among cost of sales, and general and administrative expenses. These charges mainly relate to (i) employee costs arising from the reorganization of certain business functions across the Group and (ii) employee costs associated with a business reorganization and optimization plan in Denmark.

 

(3) The income tax adjustment is calculated by multiplying the applicable nominal tax rate to the adjusting items.

Capital Employed

(Amounts in € millions)

 

 

As of March 31,

2026

 

 

As of December 31,

2025

 

 

 

 

 

 

 

 

– Goodwill and intangible assets

 

 

86.5

 

 

 

86.8

 

– Right of use assets

 

 

15.2

 

 

 

12.4

 

– Property, plant, and equipment

 

 

1,451.0

 

 

 

1,391.5

 

– Financial assets – investments FVTPL

 

 

0.1

 

 

 

0.2

 

– Other non-current financial assets

 

 

5.5

 

 

 

5.5

 

– Deferred tax assets

 

 

110.2

 

 

 

103.9

 

Non-current assets excluding FV of derivative financial instruments

 

 

1,668.6

 

 

 

1,600.3

 

 

 

 

 

 

 

 

– Inventories

 

 

294.4

 

 

 

268.2

 

– Contract assets

 

 

165.8

 

 

 

180.5

 

– Trade receivables

 

 

278.5

 

 

 

302.7

 

– Trade payables

 

 

(254.4

)

 

 

(263.3

)

– Advances from customers

 

 

(42.4

)

 

 

(33.4

)

– Non-current advances from customers

 

 

(92.2

)

 

 

(98.8

)

– Contract liabilities

 

 

(11.6

)

 

 

(10.4

)

Trade working capital

 

 

338.0

 

 

 

345.4

 

 

 

 

 

 

 

 

– Tax receivables and other receivables

 

 

53.7

 

 

 

50.6

 

– Current financial receivables – rent to buy agreement

 

 

8.7

 

 

 

8.6

 

– Tax payables and other current liabilities

 

 

(121.2

)

 

 

(100.8

)

– Current provisions

 

 

(2.3

)

 

 

(4.4

)

Net working capital

 

 

276.8

 

 

 

299.3

 

 

 

 

 

 

 

 

– Deferred tax liabilities

 

 

(14.6

)

 

 

(13.3

)

– Employees benefits

 

 

(6.8

)

 

 

(6.8

)

– Non-current provisions

 

 

(2.5

)

 

 

(3.2

)

– Other non-current liabilities

 

 

(52.9

)

 

 

(52.1

)

Total non-current liabilities and provisions

 

 

(76.8

)

 

 

(75.4

)

 

 

 

 

 

 

 

Capital employed

 

 

1,868.6

 

 

 

1,824.2

 

 

 

 

 

 

 

 

Net (debt) /cash

 

 

(337.7

)

 

 

(337.7

)

 

 

 

 

 

 

 

Total Equity

 

 

(1,530.8

)

 

 

(1,486.5

)

 

 

 

 

 

 

 

Total equity and net (debt)/ cash

 

 

(1,868.6

)

 

 

(1,824.2

)

 

 

 

 

 

 

 

Free Cash Flow

(Amounts in € millions)

 

 

 

For the three months

ended March 31,

 

 

 

2026

 

 

2025

 

Net cash flow from operating activities

 

 

75.5

 

 

 

99.8

 

Interest paid

 

 

0.8

 

 

 

1.4

 

Interest received

 

 

(0.5

)

 

 

(0.9

)

Purchase of property, plant, and equipment

 

 

(66.3

)

 

 

(70.4

)

Proceeds from sale of property, plant, and equipment

 

 

0.2

 

 

 

1.1

 

Refund of capitalized costs of property, plant, and equipment

 

 

0.1

 

 

 

 

Purchase of intangible assets

 

 

(4.5

)

 

 

(1.4

)

Free Cash Flow

 

 

5.5

 

 

 

29.7

 

Net (Debt) / Net Cash

(Amounts in € millions)

 

 

 

As of March 31,

 

 

As of December 31,

 

 

 

2026

 

 

2025

 

Non-current financial liabilities

 

 

(323.8

)

 

 

(347.4

)

Current financial liabilities

 

 

(128.3

)

 

 

(123.5

)

Other non-current financial assets – Fair value of derivatives financial instruments

 

 

0.9

 

 

 

0.3

 

Other current financial assets other than financial receivables for rent to buy agreement

 

 

1.8

 

 

 

2.2

 

Cash and cash equivalents

 

 

111.7

 

 

 

130.6

 

Net (Debt)/ Cash

 

 

(337.7

)

 

 

(337.7

)

CAPEX

(Amounts in € millions)

 

 

For the three months

ended March 31,

 

 

Change

 

 

2026

 

 

2025

 

 

 

Addition to Property, plant, and equipment

 

66.4

 

 

 

68.3

 

 

 

(1.9

)

Addition to Intangible Assets

 

1.2

 

 

 

1.4

 

 

 

(0.2

)

CAPEX

 

67.6

 

 

 

69.7

 

 

 

(2.1

)

Reconciliation of 2026 Guidance*

Reported and Adjusted EBITDA, Operating Profit, Net Profit, Diluted EPS

(Amounts in € millions, except per share data)

 

 

 

Revenue

 

EBITDA

 

Operating

Profit

 

Net Profit

 

Diluted EPS

(EUR)

Reported

 

1,260.0 – 1,290.0

 

317.7 – 332.9

 

212.7 – 227.8

 

149.6 – 160.7

 

0.55 – 0.59

Adjusting items:

 

 

 

 

 

 

 

 

 

 

Start-up costs new plants

 

 

 

14.1

 

14.1

 

10.3

 

0.04

Adjusted

 

1,260.0 – 1,290.0

 

331.8 – 346.9

 

226.8 – 241.9

 

159.9 – 171.0

 

0.59 – 0.63

*Amounts may not add due to rounding

 

Media

Caterina Tripepi

[email protected]

Investor Relations

Lisa Miles

[email protected]

Giacomo Guiducci

[email protected]

KEYWORDS: Europe United States Italy North America

INDUSTRY KEYWORDS: Biotechnology General Health Medical Devices Health Pharmaceutical

MEDIA:

Logo
Logo